Execution Version
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
Exhibit 10.1
Amended and Restated Revenue Interest Financing Agreement
This Amended and Restated Revenue Interest Financing Agreement (this “Agreement”) is entered into as of August 28, 2026 (the “A&R Effective Date”), by and between Kyntra Bio, Inc. (f/k/a FibroGen, Inc.), a Delaware corporation having an address of 350 Bay Street, Suite 100 #6009, San Francisco, CA 94133 (“Company”) and NQ Project Phoebus, L.P., a Delaware limited partnership having an address of 4208 Six Forks Road, Suite 920, Raleigh, NC 27609 (“NovaQuest”). Company and NovaQuest are each referred to herein by name or, individually, as a “Party” or, collectively, as “Parties.”
Introduction
A.Company and NovaQuest entered into that certain Revenue Interest Financing Agreement, dated as of November 4, 2022 (the “Original Agreement”), pursuant to which NovaQuest was granted an undivided percentage interest in Company’s revenue received under the Astellas Agreements, including, without limitation: (i) twenty-two and one-half percent (22.5%) of each of the Astellas EMEA Revenue, Astellas Japan Revenue and Replacement Net Sales Revenue recognized during each Fiscal Year; (ii) the applicable percentages of Astellas Other Revenue and (iii) the applicable percentages of Replacement Other Revenue. The interests attributable to the Astellas JapanAgreement granted under the Original Agreement, being twenty-two and one-half percent (22.5%) of Astellas Japan Revenue and Replacement Net Sales Revenue associated therewith recognized during each Fiscal Year and the applicable percentages of Astellas Other Revenue and Replacement Other Revenue attributable to the Astellas Japan Agreement, together with all related Revenue Interests Collateral (as defined in the Original Agreement) and other Collateral (as defined in the Original Agreement) associated therewith, are referred to herein as the “Japan Revenue Interests”.
B. As a material inducement for NovaQuest’s entry into the Original Agreement, Company granted to NovaQuest a security interest in the Collateral (as defined in the Original Agreement), including the Revenue Interests Collateral (which include the Japan Revenue Interests) (in each case, as defined in the Original Agreement), pursuant to Section 4.5of the Original Agreement.
C. Pursuant to the Original Agreement, NovaQuest paid Company the Investment Amount of Fifty Million Dollars ($50,000,000) in exchange for the Revenue Interest Payments
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
(as defined in the Original Agreement), including the Japan Revenue Interests, pursuant to and in accordance with the terms of the Original Agreement.
D. Company desires to repurchase all Repurchased Interests (as defined below in this Agreement), and NovaQuest desires to sell and return the Repurchased Interests to Company, in each case on the terms and conditions set forth in this Agreement. Company desires to repurchase the Repurchased Interests from NovaQuest (and receive the other rights and benefits afforded to the Company in this Agreement) in exchange for payment of the Repurchase Price and the Expense Payment, and NovaQuest desires to sell and return the Repurchased Interests to Company (and to be bound by the other obligations and agreements applicable to NovaQuest in this Agreement) in exchange for Company’s payment of the Repurchase Price and the Expense Payment, and, in connection therewith, the Parties desire to amend and restate the Original Agreement in its entirety on the terms and conditions set forth in this Agreement.
E. In connection with the repurchase of the Repurchased Interests and the amendment and restatement of the Original Agreement, Company is paying NovaQuest the Repurchase Price of Forty-Two Million, Five Hundred and Eighty Thousand, Five Hundred and Ninety Dollars and Sixty Six Cents ($42,580,590.66) plus the Expense Payment simultaneously with the execution of this Agreement.
F. Following the payment, and NovaQuest’s receipt, of the Repurchase Price, the Parties have agreed that the only remaining financial obligation of Company to NovaQuest under this Agreement and otherwise shall be the Capped Return Amount, being Fifteen Million Dollars ($15,000,000), plus any Adjusted Amount, reduced on a dollar-for-dollar basis by the aggregate amount of all Revenue Interest Payments received by NovaQuest after the A&R Effective Date and any full or partial prepayments of the Capped Return Amount made pursuant to Section 4.1(d)or otherwise. The Parties acknowledge and agree that all other payment obligations that would otherwise have been owed by Company under the Original Agreement (including, without limitation, all True-Up Payments, minimum amount payments under Section 4.1(b) of the Original Agreement, any Prepayment Amount (as defined in the Original Agreement), the Event of Default Fee (as defined in the Original Agreement), and any other amounts) other than the Revenue Interest Payments (for the avoidance of doubt, excluding the Japan Revenue Interests) and, in each case, subject to and capped by the Capped Return Amount, are by this Agreement eliminated in their entirety and shall have no force or effect from and after the A&R Effective Date.
G. As additional material inducement for Company’s entry into this Agreement, NovaQuest has agreed that (i) the Astellas Japan Agreement, all Astellas Japan Revenue (as defined in the Original Agreement), all Japan Revenue Interests, all Repurchased Interests and all other Collateral (as defined in the Original Agreement) related or ancillary thereto shall be forever excluded from the Collateral, the Collateral Revenue Interests, the Revenue Interest Payments from and after the A&R Effective Date and NovaQuest’s receipt of the Repurchase Price and the Expense Payment (the items, amounts and property covered by this clause (i), collectively, the “Japan Related Collateral”), (ii) Japan is not part of the Territory from and after the A&R Effective Date and (iii) NovaQuest’s security interest and Lien in the Collateral
2
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
shall no longer extend (or applicable) to the Astellas Japan Agreement, any revenue or other amounts derived therefrom or any Japan Related Collateral and all such security interests and subject to NovaQuest’s receipt of the Repurchase Price and the Expense Payment, Liens with respect to the Japan Related Collateral are hereby automatically and irrevocably forever released, terminated and discharged.
H. The Parties have agreed that the only amounts payable to NovaQuest from and after the A&R Effective Date shall be Revenue Interest Payments (for the avoidance of doubt, excluding the Japan Revenue Interests), calculated as fifty percent (50%) of Astellas EMEA Revenue and Astellas Other Revenue (excluding the Japan Revenue Interests) recognized during each Fiscal Quarter, in each case, subject to and capped by the Capped Return Amount; providedthat any Adjusted Amount shall be payable in addition to the Capped Return Amount and shall not be subject to or reduce the Capped Return Amount; provided, further, that amounts paid pursuant to clause (i) Section 4.3(a)shall reduce the Capped Return Amount on a dollar-for-dollar basis. Except for any Adjusted Amount, no other amounts shall be owed to NovaQuest under this Agreement or otherwise.
I. The Parties have agreed that Company may (but is not required to) pay the then-current Capped Return Amount to NovaQuest at any time, for any reason and without penalty, interest or any additional fee or amount, and that upon NovaQuest’s receipt of such payment (and the payment of any Adjusted Amount), this Agreement (other than Company’s indemnification obligations under ARTICLE X and any actionable claims of fraud by either of Company or NovaQuest) and all other Transaction Documents shall immediately and automatically forever terminate, all security interests and Liens granted to NovaQuest hereunder, under any other Transaction Document or otherwise (including, without limitation, on all of the Collateral) shall immediately and automatically forever be released, terminated and discharged, and NovaQuest irrevocably authorizes Company and its counsel and designees to (and, upon Company request, NovaQuest shall promptly) file termination statements and release documents and take such other actions necessary or appropriate to effectuate the foregoing and also NovaQuest shall promptly take such other actions as may be reasonably requested by Company to effectuate the release, termination and discharge of all such security interests and Liens and the foregoing.
J. Once any remedies on the Collateral are exhausted up to the Capped Return Amount (and the payment of any Adjusted Amount), no other amounts shall be owed, due or payable to NovaQuest at any time thereafter (including, with respect to any uncollected Revenue Interest payments), and this Agreement (other than Company’s indemnification obligations under ARTICLE X and any actionable claims of fraud by either of Company or NovaQuest) and all other Transaction Documents shall immediately and automatically forever terminate.
NOW, THEREFORE, in consideration of the representations, warranties, covenants and agreements set forth herein, the mutual concessions described in the foregoing recitals, and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Company and NovaQuest hereby agree as follows:
3
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
ARTICLE I
DEFINITIONS
1.1
Defined Terms. Except as otherwise expressly stated in this Agreement, when used and capitalized in this Agreement (other than the headings of the Articles and Sections), including the foregoing preamble, recitals, exhibits and schedules hereto, the following terms shall have the meanings assigned to them in this ARTICLE Iand include the plural as well as the singular and include all participles of each such term, as applicable.
“A&R Effective Date” has the meaning set forth in the preamble hereto.
“Adjusted Amount” means, collectively, (a) the Expense Payment (it being agreed that the Expense Payment was paid in full in cash on the A&R Effective Date), (b) any default interest owed, due and payable pursuant to Section 4.4, (c) any Applicable Withholding Payment, (d) any amount owed, due and payable pursuant to Section 11.2(g), and (e) any amounts owed, due and payable pursuant to Company’s indemnification obligations under ARTICLE X, in each case, if any.
“Applicable Withholding Payment” means any owed, due and payable Gross-Up Amount required to be paid by Company to (or on behalf of) NovaQuest pursuant to clause (ii) of Section 4.3(a).
“AAA” has the meaning set forth in Section 11.2(b).
“AAA Rules” has the meaning set forth in Section 11.2(b).
[*]
“Acquiring Party” means a Third Party that obtains control of Company in connection with a Change of Control of Company. For purposes of this definition, the term “control” shall have the meaning set forth in the definition of Affiliate.
“Act” means, collectively, the United States Federal Food, Drug, and Cosmetic Act of 1938, including any amendments thereto, and all regulations promulgated thereunder and any successor laws.
“Affiliate” means, with respect to an entity, any business entity controlling, controlled by, or under common control with, such entity, but only for so long as such control exists. For the purposes of this definition, “controlling,” “controlled,” and “control” mean the possession, directly (or indirectly through one or more intermediary entities), of the power to direct the management or policies of an entity, including through ownership of fifty percent (50%) or more of the voting securities of such entity (or, in the case of an entity that is not a corporation, ownership of fifty percent (50%) or more of the corresponding interest for the election of the entity’s managing authority). Notwithstanding the foregoing, for purposes of this Agreement, NovaQuest Capital Management, L.L.C. shall be deemed to have no control Persons.
4
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
“Agreement” has the meaning set forth in the preamble hereto.
“ApplicableLaw” means any applicable law, rule, or regulation of any Governmental Authority, or judgment, order, writ, decree, permit, or license of any Governmental Authority.
“Arbitration” has the meaning set forth in Section 11.2(b).
“Arbitration Notice” has the meaning set forth in Section 11.2(b).
“Arbitrator” has the meaning set forth in Section 11.2(c).
“Astellas” means Astellas Pharma Inc., a Japanese corporation with a principal place of business at 3-11 Nihonbashi-Honcho, 2-Chome, Chuo-ku, Tokyo, 103-8411 Japan.
“Astellas Agreement” means (A) prior to the A&R Effective Date, each or any of the Astellas EMEA Agreement or the Astellas Japan Agreement (“Astellas Agreements” means both of the foregoing, collectively); and (B) from and after the A&R Effective Date, solely the Astellas EMEA Agreement. For the avoidance of doubt, from and after the A&R Effective Date, the Astellas Japan Agreement shall not be an Astellas Agreement for any purpose under this Agreement.
“Astellas EMEA Agreement” means (a) that certain Anemia License and Collaboration Agreement by and between Astellas Pharma Inc. and FibroGen, Inc. dated April 28, 2006, as amended and supplemented by that certain Amendment to Anemia License and Collaboration Agreement, dated August 31, 2006, that certain Amendment No. 2, dated December 1, 2006, and that certain Amendment No. 3, dated May 10, 2012, attached hereto as Exhibit B, and as may be further amended from time to time in accordance with this Agreement and (b) that certain Astellas EU Supply Agreement dated Jan 1, 2021, as amended (“Astellas EMEA Supply Agreement”).
“Astellas EMEA Revenue” means, [*].
“Astellas Japan Agreement” means that certain Collaboration Agreement by and between Astellas Pharma Inc. and FibroGen, Inc. dated June 1, 2005, as amended January 1, 2013 and as otherwise amended from time to time. From and after the A&R Effective Date, the Astellas Japan Agreement is not an Astellas Agreement for purposes of this Agreement, and NovaQuest has no rights or interests with respect thereto.
“Astellas Japan Revenue” means, [*].
“Astellas Other Revenue” means [*] For the avoidance of doubt, from and after the A&R Effective Date, Astellas Other Revenue shall not include any amounts attributable to the Astellas Japan Agreement or any Japan Revenue Interests.
“Astellas Revenue” means (A) prior to the A&R Effective Date, collectively, the Astellas EMEA Revenue, the Astellas Japan Revenue, and the Astellas Other Revenue; and (B) from and
5
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
after the A&R Effective Date, collectively, the Astellas EMEA Revenue and the Astellas Other Revenue (as narrowed by clause (B) of the definition thereof). For the avoidance of doubt, from and after the A&R Effective Date, Astellas Revenue shall not include any Astellas Japan Revenue or any Japan Revenue Interests.
“Bankruptcy Event of Default” means any of: (a) the liquidation or dissolution of Company; (b) a Voluntary Bankruptcy; or (c) an Involuntary Bankruptcy.
“Bankruptcy Laws” means, collectively, bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, fraudulent transfer, or other similar laws affecting the enforcement of creditors’ rights generally.
“BusinessDay” means any day other than Saturday, Sunday, or any day on which banking institutions located in the State of New York are permitted or obligated by law to close.
“Capped Return Amount” means, as of any date of determination after the A&R Effective Date, (i) Fifteen Million Dollars ($15,000,000) minus (ii) the aggregate amount of (A) Revenue Interest Payments actually received in cash by NovaQuest after the A&R Effective Date [*] (B) any full or partial prepayments of the Capped Return Amount [*].
“Capped Return Payoff” has the meaning set forth in Section 4.1(d).
“Change of Control” means, with respect to Company a transaction with one or more Third Parties that is: (a) a merger, share exchange, or other reorganization of Company; (b) the sale, by one or more stockholders or holders of equity securities, of stock or equity securities representing a majority of the voting power of Company; or (c) the sale or exclusive license of all or substantially all of the assets of the Company, or a sale of Company’s business and assets related to the Product; or (d) the acquisition of majority control of the board of directors or equivalent governing body of Company, for which, in each of cases of clauses (a) and (b) of this definition, the stockholders or holders of other equity securities of Company prior to such transaction do not own a majority of the voting power of the acquiring, surviving, or successor entity, as the case may be.
“Collateral” means the Revenue Interest Collateral and the Product IP Rights. Notwithstanding anything to the contrary in this Agreement and for the avoidance of doubt, the Collateral shall exclude any Japan Related Collateral.
“Collateral Revenue Interests” means, in each case, as further described in Section 4.1(a): (A) for each Fiscal Quarter ending on or prior to June 30, 2026, (i) twenty-two and one-half percent (22.5%) of each of the Astellas EMEA Revenue, Astellas Japan Revenue, and Replacement Net Sales Revenue, (ii) ten percent (10%) of Astellas Other Revenue recognized during such period, and (iii) ten percent (10%) of Replacement Other Revenue; and (B) beginning with the Fiscal Quarter ending September 30, 2026, and solely until the Capped Return Amount is reduced to zero, (i) fifty percent (50%) of Astellas EMEA Revenue recognized during each Fiscal Quarter, (ii) fifty percent (50%) of Astellas Other Revenue (as narrowed by clause (B) of the definition thereof) recognized during each Fiscal Quarter, (iii) fifty percent
6
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
(50%) of Replacement Net Sales Revenue recognized during each Fiscal Quarter, and (iv) fifty percent (50%) of Replacement Other Revenue recognized during each Fiscal Quarter. For the avoidance of doubt, from and after the A&R Effective Date, (a) the Collateral Revenue Interests shall not include any interest in Astellas Japan Revenue, Japan Revenue Interests or Japan Related Collateral and (b) all Collateral Revenue Interests (including those attributable to Replacement Net Sales Revenue and Replacement Other Revenue) received for each Fiscal Quarter ending on or after September 30, 2026 shall be subject to and capped by the Capped Return Amount.
“Commercially Reasonable Efforts” means, [*].
“Commercialize” or “Commercialization” means any and all activities directed to marketing, promoting, distributing, importing, exporting, offering to sell, or selling the Product, including commercial manufacturing activities.
“Company” has the meaning set forth in the preamble hereto.
“Company Competitor” means any Person that, in the Fiscal Year preceding the date of determination, derived more than [*] of its revenue from its or its Affiliates’ direct sales of pharmaceutical products.
“Compound” means Roxadustat, as more particularly described in Exhibit D.
“Confidential Information” has the meaning set forth in Section 6.1.
“Cover” means that the use, manufacture, sale, offer for sale, development, commercialization, or importation of the subject matter in question by an unlicensed entity would infringe a claim of an issued Patent, or a claim, if issued, of a patent application that constitutes a Patent.
“Custodian” means any receiver, trustee, assignee, liquidator, custodian, or similar official under any Bankruptcy Law.
“Default” means any event that, with the giving of notice or passage of time, or both, could result in an Event of Default.
“Defaulting Party” has the meaning set forth in Section 8.6(d)(iii).
“Dispute” has the meaning set forth in Section 11.2(a).
“DisputeNotice” has the meaning set forth in Section 11.2(a).
“Dollars” or “$” means U.S. dollars.
“Effective Date” means November 4, 2022, being the date of the Original Agreement.
7
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
“Encumbrance” means any lien, charge, security interest, mortgage, option, privilege, pledge, right of first refusal, hypothecation, adverse ownership interest, charge, trust or deemed trust (whether contractual, statutory, or otherwise arising), or any other encumbrance, right, or claim of any other Person of any kind whatsoever whether choate or inchoate. “Encumber” means to restrict, impose, suffer, or otherwise create any Encumbrance.
“ESG Questionnaires” has the meaning set forth in Section 5.4.
“Event of Default” means each or any of: (a) the failure by Company to pay any Revenue Interest Payment or any Adjusted Amount due to NovaQuest under this Agreement when required to be paid, which failure continues for more than [*] after Company’s receipt of written notice from NovaQuest specifying such failure; (b) a Bankruptcy Event of Default; (c) a Change of Control occurs and Company fails to comply with Section 8.4; (d) the sale, transfer, or other disposition of a material portion of the Collateral by Company (other than in the ordinary course of business) without NovaQuest’s prior written consent; or (e) Company materially breaches its obligations under Section 8.6(d)with respect to the Astellas EMEA Agreement and such breach remains uncured for [*] after Company’s receipt of written notice from NovaQuest specifying such breach and where such breach, if not cured, would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.
“Excluded Taxes” means any of the following Taxes imposed on or with respect to NovaQuest or required to be withheld or deducted from payment to NovaQuest: (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case (i) imposed as a result of NovaQuest being organized under the laws of, or having its principal office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes and (b) Taxes to the extent solely attributable to NovaQuest or any of its Affiliates changing its jurisdiction of domicile or form of legal entity or from NovaQuest assigning its rights or obligations under the Funding Agreement. For the purposes of the definition of “Excluded Taxes,” the term “NovaQuest” includes any successors or assignees of NovaQuest according to Section 11.6.
“Expense Payment” has the meaning set forth in Section 11.4.
“FDA” means the United States Food and Drug Administration, or any successor agency thereto.
“Fiscal Quarter” means each of the following three (3)‑month periods during each Fiscal Year: January 1 through March 31; April 1 through June 30; July 1 through September 30; and October 1 through December 31.
“Fiscal Year” means the twelve (12)‑month period from January 1 through December 31.
“GAAP” means U.S. generally accepted accounting principles, as in effect on the date or for the period with respect to which such standards are applied.
8
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
“Governmental Authority” means any national, supra‑national (e.g., the European Commission or the Council of the European Union), federal, state, local, or foreign court or governmental agency, authority, instrumentality, regulatory body, department, bureau, political subdivision, or other governmental entity (including the FDA, the European Medicines Agency, the Japanese Ministry of Health, Labour and Welfare or Pharmaceuticals and Medical Devices Agency, and the Medicines and Health Products Regulatory Agency, as well as any similar regulatory body in any country in the Territory) or any arbitrational tribunal, in each case of a competent jurisdiction, including any such authority that is responsible for taxation or for issuing approvals, licenses, registrations, or authorizations necessary for the manufacture, import, sale, pricing, or use of the Product for human therapeutic use in any applicable regulatory jurisdiction.
“Gross‑Up Amount” has the meaning set forth in Section 4.3(a).
“GxP” means all relevant Governmental Authority requirements for: (a) current Good Clinical Practices for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials; (b) current Good Laboratory Practice for laboratory activities for pharmaceuticals; and (c) current Good Manufacturing Practices, including in each case, as set forth in Title 21 of the United States Code of Federal Regulations.
“IFRS” means international accounting standards, as in effect on the date or for the period with respect to which such standards are applied, as established by the International Financial Reporting Standards.
“Indebtedness” means, with respect to a Person: (a) all obligations of such Person for borrowed money; (b) all obligations of such Person evidenced by a note, bond, debenture, or similar instrument; (c) all obligations of such Person upon which interest charges are customarily paid; (d) all obligations of such Person under conditional sale or other title retention agreements relating to property acquired by such Person; (e) all obligations of such Person in respect of the deferred purchase price of property or services (excluding deferred compensation and accounts payable incurred in the ordinary course of business and not overdue by more than [*]; (f) all Indebtedness as described in clauses (a) through (e) or clauses (h) through (l) of others secured by (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on property owned or acquired by such Person if the Indebtedness secured thereby has been assumed; (g) all guarantees by such Person of Indebtedness as described in clauses (a) through (e) or clauses (h) through (l) of others; (h) all capital lease obligations of such Person; (i) all obligations, contingent or otherwise, of such Person as an account party in respect of letters of credit and letters of guaranty; (j) all net obligations of such Person under any interest rate exchange agreement, foreign currency exchange agreement, commodity price protection agreement, currency swap, forward, future or derivative transactions or other interest or currency exchange rate or commodity price hedging arrangement; (k) all obligations, contingent or otherwise, of such Person in respect of bankers’ acceptances; and (l) any disqualified equity interests of such Person.
“Investment Amount” has the meaning set forth in Section 3.1(a).
9
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
“Investor Return Payment” means each or any of the Revenue Interest Payments. For the avoidance of doubt, from and after the A&R Effective Date, Investor Return Payments shall not include any True-Up Payments, minimum amount payments under Section 4.1(b)of the Original Agreement, any Prepayment Amount (as defined in the Original Agreement), the Event of Default Fee (as defined in the Original Agreement), any payment with respect to Japan Revenue Interests and any other amounts.
“Investor Return Payment Satisfaction” means the earlier to occur of: (a) such time as the Capped Return Amount has been finally reduced to $0; and (b) such time as Company has paid the then-current Capped Return Amount to NovaQuest pursuant to Section 4.1(d).
“Involuntary Bankruptcy” means a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that: (a) is for relief against Company in an involuntary case; (b) appoints a Custodian of Company or for any substantial part of its property; or (c) orders the winding up or liquidation of Company; or any similar relief is granted under any non-U.S. laws, and in each case ((a)–(c)), such order or decree remains unstayed and in effect for [*].
“Japan Related Collateral” has the meaning set forth in Recital G.
“Japan Revenue Interests” has the meaning set forth in Recital A.
“Knowledge of Company” or “Knowledge” means the actual knowledge, after making reasonable inquiry, of [*].
“Liabilities” means any and all indebtedness, liabilities, and obligations, whether accrued, fixed, or contingent, mature or inchoate, known or unknown, reflected on a balance sheet or otherwise, including those arising under any law or judgment of any court of any kind or any award of any arbitrator of any kind, and those arising under any contract, commitment, or undertaking.
“License” means (i) prior to the A&R Effective Date, a grant of any Product IP Rights or Regulatory Approvals for making, developing, Commercializing or otherwise exploiting the Product in the Territory, including, for the avoidance of doubt, each of the Astellas EMEA Agreement, the Astellas Japan Agreement, and any Replacement Agreement; and (ii) from and after the A&R Effective Date, a grant of any Product IP Rights or Regulatory Approvals for making, developing, Commercializing or otherwise exploiting the Product in the Territory, including, for the avoidance of doubt, the Astellas EMEA Agreement and any Replacement Agreement, but excluding in all cases the Astellas Japan Agreement, the Japan Related Collateral and any agreement, arrangement, or revenue derived therefrom, which shall not be a License for any purpose under this Agreement from and after the A&R Effective Date.
“Licensee” means a Third Party or an Affiliate of Company that is granted a License, by Company, an Affiliate of Company, or another Licensee. For the avoidance of doubt, (a) Astellas is a Licensee and (b) any Third Party that enters into a Replacement Agreement with Company or with any Affiliate of Company shall be a Licensee.
10
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
“Lien” means any mortgage, lien, pledge, participation interest, charge, adverse claim, security interest, encumbrance or restriction of any kind, whether voluntarily incurred and arising by operation by law or otherwise, including any restriction on use, transfer or exercise of any other attribute of ownership of any kind.
“Losses” has the meaning set forth in Section 10.1.
“Material Adverse Effect” means any material adverse effect on: (a) the ability of the Company to make the Revenue Interest Payments required to be made by this Agreement; (b) the Commercialization of the Product in the Territory; (c) for the purpose of Section 7.1only, any of the Product IP Rights, including Company’s rights in or to any Product IP Rights; (d) for the purpose of Section 7.1only, any Regulatory Approval granted prior to the Effective Date for the Product in the Territory; (e) for the purpose of Section 7.1only, the legality, validity, or enforceability of any Astellas Agreement or Transaction Document; (f) the ability of Company to perform any of its material obligations under any Astellas Agreement or Transaction Document, or to consummate the transactions contemplated hereby or thereby; or (g) the rights or remedies of NovaQuest under any Transaction Document; providedthat no material adverse effect on anything related to the Astellas Japan Agreement or any agreement related to Japan Revenue Interests or Japan Related Collateral shall be a Material Adverse Effect unless it also constitutes a material adverse effect under clause (a) above.
“Material Contract” means: (a) any agreement to which Company or any Affiliate of Company is a party and is material to the Commercialization of the Product in the Territory; or (b) any other agreement to which Company or any Affiliate of Company is a party for which breach, non-performance, or failure to renew by a Responsible Party could reasonably be expected to result in a Material Adverse Effect; [*].
“NDA” means a new drug application (as defined in Title 21 of the U.S. Code of Federal Regulations, as amended from time to time) submitted to the FDA seeking approval to introduce, distribute, sell, or market a drug product for human therapeutic use in the U.S. (including a new drug application submitted under Section 505(b)(2) of the Act) and the foreign equivalent in any country in the Territory.
“NovaQuest” has the meaning set forth in the preamble hereto.
“NovaQuest Indemnitees” has the meaning set forth in Section 10.1.
“Original Agreement” has the meaning set forth in Recital A.
“Other Connection Taxes” means, with respect to NovaQuest, Taxes imposed as a result of a present or former connection between NovaQuest and the jurisdiction imposing such Tax (other than connections arising from NovaQuest having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced this Agreement). For the purposes of the definition of “Other Connection Taxes,” the term “NovaQuest” includes any successors or assignees of NovaQuest according to Section 11.6.
11
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
“Parties” has the meaning set forth in the preamble hereto.
“Party” has the meaning set forth in the preamble hereto.
“Patents” means all patents (including all reissues, extensions, substitutions, confirmations, re‑registrations, re‑examinations, revalidations, supplementary protection certificates, and patents of addition) and patent applications (including all provisional applications, continuations, continuations‑in‑part, and divisions) and all counterparts and equivalents of any of the foregoing in any country or jurisdiction.
“Payment Cap” has the meaning given to “Capped Return Amount.”
“Payment Report” has the meaning set forth in Section 4.1(f).
“Permitted Company” means [*].
“Permitted Encumbrance” means
(a) Encumbrances imposed by law, such as carriers’, warehousemen’s, landlords’, materialmen’s, repairman’s, construction contractors’, mechanics’, airports’, navigation authority’s or other like Encumbrances, in each case for sums not yet overdue by more than [*] or being contested in good faith by appropriate proceedings or other Encumbrances arising out of judgments or awards against such Person with respect to which such Person shall then be proceeding with an appeal or other proceedings for review (or which, if due and payable, are being contested in good faith by appropriate proceedings and for which adequate reserves are being maintained, to the extent required by IFRS);
(b) Encumbrances for taxes, assessments or other governmental charges or levies (i) which are not yet overdue for [*] or not yet due or payable, (ii) which are being contested in good faith by appropriate proceedings and (iii) for which adequate reserves are being maintained to the extent required by IFRS or GAAP;
(c) Encumbrances securing indebtedness (including, without limitation, capital lease obligations and purchase money obligations) incurred by the Company to finance all or any part of the purchase, lease, construction, installation, repair or improvement of property (real or personal), plant or equipment or other fixed or capital assets; provided such lien extends only to the assets the acquisition, lease, construction, repair, replacement or improvement of which is financed thereby and any replacements, additions and accessions thereto and any income or profits thereof;
(d) Encumbrances on specific items of inventory or other goods and proceeds of any Person securing such Person’s obligations in respect of bankers’ acceptances or letters of credit entered into in the ordinary course of business issued or created for the account of such Person to facilitate the purchase, shipment or storage of such inventory or other goods;
12
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
(e) grants of software, technology and other intellectual property licenses in the ordinary course of business;
(f) Encumbrances in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation and exportation of goods in the ordinary course of business;
(g) [*];
(h) the Encumbrances or Liens granted in favor of NovaQuest pursuant to this Agreement; and
(i) Encumbrances arising solely by virtue of any statutory or common law provision or customary business provision relating to banker’s encumbrances, rights of set-off or similar rights.
“Person” means any natural person, corporation, trust, joint venture, association, unincorporated organization, cooperative, company, partnership, trust, limited liability company, government (domestic or foreign), and any agency or instrumentality thereof, or any other entity recognized by law.
“Prepayment” has the meaning given to “Capped Return Payoff” in Section 4.1(d).
“Prepayment Amount” has the meaning given to “Capped Return Amount.”
“Prime Rate” has the meaning set forth in Section 4.4.
“Product” means any prescription pharmaceutical product that contains the Compound.
“Product IP Rights”means all of the following intellectual property owned or licensed by the Company, in each case, as they exist in the Territory and solely as necessary or useful to the manufacturing, development or Commercialization of the Product in the Territory: (a) the Product Know‑How; (b) the Product Patents; and (c) all trademarks, service marks, trade names, and works protectable under copyright laws.
“Product Know‑How” means, with respect to the Product in the Territory, all trade secrets, technology, processes, practices, formulae, instructions, procedures, assembly procedures, results (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, preclinical, clinical, safety, manufacturing and quality control data, including study designs and protocols), know-how, methods, treatments, techniques, systems, designs, artwork, drawings, plans, specifications, data and information, in each case whether or not confidential, proprietary, patentable, copyrightable, or susceptible to any other form of legal protection, in written, electronic or any other form.
“Product Patents” has the meaning set forth in Section 7.1(e).
13
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
“Quarterly Report” means a report submitted by Company to NovaQuest in accordance with the provisions of Section 3.1(b), that contains (a) the information from quarterly reports in respect of the preceding Fiscal Quarter or other reports and material correspondence received from Astellas during the preceding Fiscal Quarter under its obligations under the Astellas Agreements relating to Commercialization of the Product in the Territory; (b) a statement setting forth Company’s good faith qualitative assessment of Astellas’s performance of its obligations under the Astellas Agreements relating to Commercialization of the Product in the Territory during the preceding Fiscal Quarter; and (c) at any time after the termination of any Astellas Agreement and Company’s entry into a Replacement Agreement, information similar to the information set forth in clauses (a) and (b) of this definition to the extent received from any Responsible Party or to the extent pertaining to such Responsible Party’s performance under the applicable Replacement Agreement. All amounts in each Quarterly Report shall be denominated in Dollars. Notwithstanding the foregoing, Company may, at its election, deliver the information contemplated herein and therein via disclosures made pursuant to Company’s public reporting requirements, by delivery of summaries, reports, or presentations to NovaQuest, or by providing excerpts of materials presented to the Company’s board of directors or executive leadership team.
“Recordkeeping Period” has the meaning set forth in Section 5.2(a).
“Register” has the meaning set forth in Section 11.6.
“Regulatory Approval” means, with respect to the Product, in any country or jurisdiction, any approval, registration, license, or authorization that is required by the applicable Governmental Authority to market and sell such Product in such country or jurisdiction.
“Regulatory Filing” means any application, filing, or submission required by or provided to a Governmental Authority relating to the development, manufacture, Commercialization, pricing, or other exploitation of the Product, including any supporting documentation, correspondence, meeting minutes, amendments, supplements, registrations, licenses, regulatory drug lists, advertising and promotion documents, adverse event files, complaint files, and manufacturing, shipping, or storage records with respect to any of the foregoing, including an NDA, drug master filing, clinical trial application, and any counterparts or equivalents of any of the foregoing.
“Replacement Agreement” means an agreement entered into between Company or any Affiliate of Company and a Third Party following the termination (in whole or in part) of any Astellas Agreement in which Company grants a License or otherwise transfers any of the Product IP Rights in the Territory or other rights that are relevant to making, using, selling, offering for sale, or importation of the Product in the Territory. Agreements expressly considered Replacement Agreements include: (x) exclusive licenses, option agreements, right of first refusal agreements, non-assertion agreements, distribution agreements that grant or otherwise transfer any Product IP Rights in the Territory, or similar agreements; and (y) agreements that grant or otherwise transfer rights in the Product IP Rights along with rights owned by Company or any Affiliate of Company or granted to Company or any Affiliate of Company by a Third Party. For the avoidance of doubt, (I) Replacement Agreement excludes any or all of the Astellas
14
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
Agreements, (II) the Astellas Japan Agreement and all of the agreements, documents and other terms used in this definition related thereto or associated therewith or related solely to or associated solely with Japan are excluded from this definition and (III) no Replacement Agreement shall solely relate to or be solely associated with Japan, the Astellas Japan Agreement or Japan Revenue Interests.
“Replacement Net Sales Revenue” means any payments based on sales of the Product in the Territory received by Company or any of its Affiliates under or pursuant to a Replacement Agreement. For the avoidance of doubt, (a) Replacement Net Sales Revenue excludes Astellas EMEA Revenue, Astellas Japan Revenue, and Astellas Other Revenue, (b) the Japan Revenue Interests and any replacement of such revenue or amounts by anything else, and any other payments or amounts related solely to or associated solely with Japan, are excluded from Replacement Net Sales Revenue, and (c) any Replacement Net Sales Revenue shall be subject to and capped by the Capped Return Amount.
“Replacement Other Revenue” means any revenue, other than Replacement Net Sales Revenue, recognized by Company or any of its Affiliates under or pursuant to a Replacement Agreement attributable to payments for the Product in the Territory. For the avoidance of doubt, (a) Replacement Other Revenue excludes Astellas EMEA Revenue, Astellas Japan Revenue, and Astellas Other Revenue, (b) the Japan Revenue Interests and any other revenue related solely to or associated solely with Japan are excluded from Replacement Other Revenue, and (c) any Replacement Other Revenue shall be subject to and capped by the Capped Return Amount.
“Repurchase Price” means Forty-Two Million, Five Hundred and Eighty Thousand, Five Hundred and Ninety Dollars and Sixty Six Cents ($42,580,590.66).
“Repurchased Interests” means all of NovaQuest’s right, title and interest in and to the Astellas Japan Agreement, the Astellas Japan Revenue (including the portion of Astellas Other Revenue attributable to the Astellas Japan Agreement), the Japan Revenue Interests and all related Collateral Revenue Interests, Revenue Interest Payments and Revenue Interest Collateral associated therewith, which rights, title and interests are being repurchased by Company from NovaQuest in exchange for the Repurchase Price pursuant to this Agreement.
“Responsible Party” means Company, Astellas, its and their respective Affiliates and Licensees, and any Acquiring Party.
“Revenue Interest Collateral” means the [*]; providedthat no Japan Revenue Interests or Japan Related Collateral shall constitute Revenue Interest Collateral.
“Revenue Interests” means [*] and (b) excludes all Japan Revenue Interests.
“Revenue Interest Payment” has the meaning set forth in Section 4.1(a). “Revenue Interest Payments” means the Revenue Interest Payment, collectively. Notwithstanding anything to the contrary and for the avoidance of doubt, the Revenue Interest Payment and the Revenue Interest Payments exclude all rights and payments with respect to the Japan Revenue Interests.
15
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
“Sales Forecast” has the meaning set forth in Section 5.1(b).
[*]
[*]
[*]
“Senior Officer” means: (a) in the case of NovaQuest, its chief investment officer; and (b) in the case of Company, its Chief Executive Officer.
[*]
“Tax” means any present or future tax, levy, impost, duty, assessment, charge, fee, deduction, or withholding in the nature of a tax and whatever called (including interest and penalties thereon) imposed, levied, collected, withheld, or assessed by any Governmental Authority.
“Term” has the meaning set forth in Section 9.1.
“Territory” means each or any of the following countries, individually or collectively: Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Kyrgyzstan, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Moldova, Monaco, Netherlands, Norway, North Macedonia, Poland, Portugal, Romania, Russia, San Marino, Serbia and Montenegro (Yugoslavia), Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Tajikistan, Turkey, Turkmenistan, Ukraine, United Kingdom, Uzbekistan, Vatican City, Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syria, United Arab Emirates, Yemen (and solely prior to the A&R Effective Date, Japan), and any other country in which Astellas has rights to Commercialize the Product (an “Additional Country”) (provided that any such Additional Country shall be included in the Territory only if and to the extent Astellas is Commercializing the Product in such Additional Country); provided, however, that from and after the A&R Effective Date, Japan shall be excluded from the Territory for all purposes under this Agreement.
“Third Party” means any Person, including a Governmental Authority, other than Company, NovaQuest, and each of their respective Affiliates. “Third-Party” has the corresponding meaning.
“Transaction Documents” means this Agreement, [*], and any other documents, instruments, or financing statements required to be delivered hereunder or thereunder or in connection herewith or therewith.
“True-Up Payment” has the meaning set forth in the Original Agreement.
16
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
“UCC” means the Uniform Commercial Code as in effect from time to time in the State of New York, provided that if, with respect to any financing statement or by reason of any provisions of applicable law, the perfection or the effect of perfection or non-perfection of the security interest or any portion thereof granted pursuant to Section 4.5 is governed by the Uniform Commercial Code as in effect in a jurisdiction of the United States other than the State of New York, then “UCC” means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions of this Agreement and any financing statement relating to such perfection or effect of perfection or non-perfection.
“United States” or “U.S.” means the United States of America, including its territories and possessions.
“Voluntary Bankruptcy” means Company, pursuant to or within the meaning of any Bankruptcy Law: (a) commences a voluntary case; (b) consents to the entry of an order for relief against it in an involuntary case; (c) consents to the appointment of a Custodian of it or for any substantial part of its property; or (d) makes a general assignment for the benefit of its creditors or takes any comparable action under any non-U.S. laws relating to insolvency.
“Voluntary Transfer” means with respect to NovaQuest, or any of its Affiliates (to the extent relevant): (a) the sale or disposition of all or substantially all of the assets of such Party; (b) the sale or transfer of more than [*] of the voting power of the outstanding voting securities of such Party or any Affiliate of such Party that directly or indirectly controls (as defined in the definition of Affiliate) such Party; (c) the merger or consolidation of such Party or any Affiliate of such Party that directly or indirectly controls (as defined in the definition of Affiliate) such Party, with or into another entity Person; or (d) the assignment by such Party of this Agreement or all or any portion of the rights and obligations hereunder.
“Withholding Payment” has the meaning set forth in Section 4.3(a).
ARTICLE II
SCOPE OF AGREEMENT
2.1
General Agreement. Each Party represents and warrants to the other Party that, as of the A&R Effective Date, to such Party’s Knowledge, no breach, violation, Default or Event of Default exists under the Original Agreement, this Agreement or any other Transaction Document (including any facts, circumstances, or events that, alone or together with other facts, circumstances, or events, such Party reasonably expects would, with the giving of notice or passage of time, or both, give rise to a breach, violation, Default or Event of Default). In addition to the Repurchase Price and the Expense Payment paid simultaneously by Company to NovaQuest with the execution of this Agreement, and in consideration for the Parties’ entry into this Agreement: (a) Company shall make payments to NovaQuest as expressly set forth in and subject to the limitations of Article IV, including Section 4.1(e), and subject to the Capped Return Amount, and (b) except for any Adjusted Amount, NovaQuest shall be entitled under this Agreement and otherwise to no more than the Capped Return Amount.
17
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
2.2
Preamble, Recitals and Definitions. Notwithstanding anything to the contrary in this Agreement or otherwise, the preamble, recitals, definitions and all of the other foregoing provisions in this Agreement shall be deemed to be incorporated into the body of this Agreement and shall be deemed to be agreements that all Parties are bound.
2.3
Limitations. Company accepts, acknowledges, and agrees that NovaQuest is agreeing, on the terms and conditions set forth in this Agreement, only to satisfy the funding obligations set forth in Section 3.1(a)and its other obligations expressly set forth herein and is not assuming any Liability of Company, of whatever nature, whether presently in existence or arising or asserted hereafter.
ARTICLE III
NOVAQUEST FUNDING; COMMERCIALIZATION
3.1
NovaQuest’s Funding Obligation.
(a)
Investment Amount. On the Effective Date, NovaQuest paid Company an amount equal to Fifty Million Dollars ($50,000,000) (the “Investment Amount”). The Investment Amount has been paid in full and NovaQuest has no further funding obligations under this Agreement.
(b)
Quarterly Reports. Beginning with the first full Fiscal Quarter that commences after the A&R Effective Date and for each subsequent Fiscal Quarter during the Term, Company shall deliver a complete and accurate Quarterly Report to NovaQuest within [*] following the first Business Day of such Fiscal Quarter; provided that, in the event that Astellas is delayed in providing the Company with any information required to be contained in a Quarterly Report, the Company will notify NovaQuest of such delay in the Quarterly Report and will subsequently provide NovaQuest with the relevant delayed Quarterly Report information within [*] after Company receives the relevant delayed Quarterly Report information from Astellas.
(c)
Miscellaneous. For the avoidance of doubt, NovaQuest has no further payment obligations under this Section 3.1.
3.2
Diligence. During the Term, Company shall use [*] to ensure that a Permitted Company is Commercializing the Product in the Territory in each country where the Product has received Regulatory Approval (other than, for the avoidance of doubt, Japan).
ARTICLE IV
PAYMENTS TO NOVAQUEST
4.1
Payments and Reports.
(a)
Revenue Interest Payments. [*], Company shall pay to NovaQuest a payment (each such payment, a “Revenue Interest Payment”) in an amount equal to the Collateral
18
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
Revenue Interests for such Fiscal Quarter, calculated in accordance with the definition of Collateral Revenue Interests. Revenue Interest Payments [*] shall be subject to and applied against the Capped Return Amount. Each Revenue Interest Payment calculated under clause (B) of the definition of Collateral Revenue Interests are, for the avoidance of doubt, as follows:
(i)
fifty percent (50%) of Astellas EMEA Revenue recognized during such Fiscal Quarter; plus
(ii)
fifty percent (50%) of Astellas Other Revenue recognized during such Fiscal Quarter; plus
(iii)
fifty percent (50%) of Replacement Net Sales Revenue recognized during such Fiscal Quarter; plus
(iv)
fifty percent (50%) of Replacement Other Revenue recognized during such Fiscal Quarter.
In no event shall the aggregate Revenue Interest Payments actually received in cash by NovaQuest [*] exceed Fifteen Million Dollars ($15,000,000) (i.e., the Capped Return Amount in effect as of the A&R Effective Date) (for the avoidance of doubt, any owed, due and payable Adjusted Amount is in excess of the Capped Return Amount). Only Revenue Interest Payments actually received in cash by NovaQuest [*] shall reduce the Capped Return Amount on a dollar-for-dollar basis. The Repurchase Price and all amounts attributable to [*] shall be separately treated and shall not reduce the Capped Return Amount. No adjustment, true-up or other calculation shall require NovaQuest to make any affirmative payment or repayment to Company, whether before or after the Capped Return Amount has been reduced to zero.
[*].
(b)
[Reserved].
(c)
[Reserved].
(d)
Capped Return Payoff. Notwithstanding any other provision of this Agreement, Company may pay the then-current remaining Capped Return Amount to NovaQuest at any time during the Term, for any reason and without penalty or premium, by wire transfer of immediately available funds and written notice designating such payment as a Capped Return Payoff pursuant to this Section 4.1(d)(such payment, a “Capped Return Payoff”). Company and NovaQuest agree that any Capped Return Payoff shall be deemed to be due and payable to NovaQuest upon its receipt.
(e)
Capped Return Amount; Termination.
(i)
Company’s obligation to make any Investor Return Payments to NovaQuest will terminate upon the achievement of Investor Return Payment Satisfaction. For
19
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
clarity, upon the achievement of Investor Return Payment Satisfaction, this Agreement and the other Transaction Documents will terminate in accordance with Section 9.2(b).
(ii)
Notwithstanding anything to the contrary in this Agreement or any other Transaction Document, all Revenue Interest Payments received by NovaQuest from (or on behalf of) Company shall be applied first to reduce the Capped Return Amount, and, after the occurrence and during the continuance of an Event of Default upon the foreclosure of the Collateral by NovaQuest, NovaQuest shall be entitled to receive one hundred percent (100%) of the amounts from exercising rights and remedies on the Collateral until the Capped Return Amount has been reduced to zero, plus any Adjusted Amount, at which point all further amounts from the Collateral and the Revenue Interest Payments shall belong solely to (and be held in trust for and immediately paid over to) Company.
(f)
Payment Reports. Commencing with the Fiscal Quarter in which the A&R Effective Date occurs and continuing for each Fiscal Quarter until the achievement of Investor Return Payment Satisfaction, Company shall, simultaneously with its delivery of a Revenue Interest Payment pursuant to Section 4.1(a)or, if no Revenue Interest Payment is due, [*] of the end of the applicable Fiscal Quarter, prepare and deliver a written report to NovaQuest that includes (to the extent received from a Responsible Party or otherwise reasonably available to the Company) reasonably detailed information regarding the total monthly sales of the Product on a country-by-country basis in such Fiscal Quarter in the Territory, including the amounts of gross sales of the Product per country in the Territory, and a calculation of the Astellas EMEA Revenue, Astellas Other Revenue, and the applicable Revenue Interest Payment payable to NovaQuest which are attributable to each country for such Fiscal Quarter (including any foreign exchange rates employed) (such written report, a “Payment Report”).
4.2
NovaQuest’s Account. All payments under this Agreement to NovaQuest shall be made in Dollars by wire transfer in immediately available funds to such accounts as NovaQuest designates in writing from time to time.
4.3
Taxes; Withholding.
(a)
If any Governmental Authority requires (i) Company to deduct or withhold any amount from any payment by Company to NovaQuest, or (ii) NovaQuest to pay any present or future Tax, assessment, or other governmental charge on, any payment by Company to NovaQuest (in each case, a “Withholding Payment” ), then Company shall, in addition to paying NovaQuest the amount reduced by such Withholding Payment, simultaneously pay NovaQuest an additional amount such that NovaQuest receives the full contractual amount of the applicable payment as if no such Withholding Payment had occurred (such additional amount, the “Gross-Up Amount”); provided, that Company shall not be required to pay such additional amounts with respect to any Withholding Payment that is attributable to any Excluded Taxes.
(b)
Notwithstanding Section 4.3(a), if a Withholding Payment is required solely as a result of (i) a Voluntary Transfer by NovaQuest after the Effective Date of this Agreement or (ii) the failure to provide an IRS Form W-9 pursuant to Section 4.3(c), then Company shall not be obligated to pay NovaQuest the Gross-Up Amount with respect to such Withholding Payment.
20
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
(c)
NovaQuest and any permitted transferee or assignee hereunder shall deliver at the closing, and at any other times as reasonably requested by the Company or required by law to reduce the amount of withholding, a properly completed IRS Form W-9 certifying that NovaQuest (or such permitted transferee or assignee) is exempt from “backup” withholding tax.
(d)
If Company is required to make a Withholding Payment to a Governmental Authority, Company shall deliver to NovaQuest the original or a certified copy of a receipt issued by such Governmental Authority evidencing its payment of such Withholding Payment.
(e)
After the A&R Effective Date, the contingent Revenue Interest Payments that have yet to become owed, due and paid as of any applicable time are not intended by the Parties to be treated as debt or equity for Tax purposes. If there is an inquiry by any Governmental Authority of Company or NovaQuest related to this Section 4.3(e), the Parties shall cooperate with each other in responding to such inquiry in a commercially reasonable manner consistent with this Section 4.3(e)and Applicable Law.
4.4
Interest. If any payment required to be paid by Company to NovaQuest under this Agreement is not made when due, then such outstanding payment will accrue interest, beginning on the date when the payment was due and ending (but not including) the date such payment is made, at an annual rate equal to [*] plus the Prime Rate, subject to any limitation under Applicable Law. Such rate will be compounded every [*], commencing on the date on which such payment was due and ending (but not including) the date such payment is made. Payment of accrued interest will accompany payment of the outstanding payment. “Prime Rate” means the prime rate as reported in The Wall Street Journal, New York edition, on the date such payment is due.
4.5
Grant of Security Interest.
(a)
For value received and to secure the prompt and complete payment and performance of all payment obligations of Company now or hereafter owing, due and payable to NovaQuest under Section 4.1and in respect of any Adjusted Amount, the Company does hereby: (i) grant to NovaQuest a security interest in and to all right, title and interest in, to and under the Collateral; and (ii) authorize NovaQuest, from and after the Effective Date, to file such financing statements and continuation statements with respect to such financing statements when applicable, in such manner and such jurisdictions as are necessary or appropriate to perfect the security interest granted hereunder; provided, that the description of the Collateral in such financing statements and continuation statements shall not be broader than the definition of the Collateral hereunder (for the avoidance of doubt, after giving effect to this Agreement).
(b)
Subject to Section 4.5(d), Company agrees that from time to time, Company will, in a commercially reasonable manner, execute and deliver all further instruments and documents, and take all further actions, that NovaQuest may reasonably request and that are required in order to perfect and protect the security interest granted in the Collateral hereby, to create, perfect or protect the security interest purported to be granted hereby or to enable NovaQuest to exercise and enforce its rights and remedies hereunder with respect to any of the Collateral, including, but not limited to, entering into United States law governed intellectual property security agreements
21
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
with respect to the Product IP Rights and filing such agreements with the United States Patent and Trademark Office, as necessary, [*].
(c)
Following the payment of the Capped Return Amount (and the payment of any Adjusted Amount), this Agreement (other than Company’s indemnification obligations under ARTICLE X and any actionable claims of fraud by either of Company or NovaQuest) and all other Transaction Documents shall immediately and automatically forever terminate, all security interests and Liens granted to NovaQuest hereunder, under any other Transaction Document or otherwise (including, without limitation, on all of the Collateral) shall immediately and automatically forever be released, terminated and discharged, and NovaQuest irrevocably authorizes Company and its counsel and designees to (and, upon Company request, NovaQuest shall promptly) file termination statements and release documents and take such other actions necessary or appropriate to effectuate the foregoing and also NovaQuest shall promptly take such other actions as may be reasonably requested by Company to effectuate the release, termination and discharge of all such security interests and Liens and the foregoing. [*].
(d)
Notwithstanding any provision herein to the contrary, the Company shall not be required to execute or deliver any instrument or document or take any further actions, in each case, with respect to any Collateral (other than the filing of a UCC-1 financing statement against the Company in its jurisdiction of incorporation and an intellectual property security agreement to be filed with the United States Patent and Trademark Office) if any of the following apply:
(i)
[*];
(ii)
the burden or cost of obtaining a grant of a security interest therein or perfection thereof (including any burden resulting from a change to the ordinary course business operations of Company or from any third party consent required for any such grant or perfection) exceeds the practical benefit to NovaQuest afforded thereby as reasonably mutually determined by Company and NovaQuest;
(iii)
such actions would contravene, violate, cause a breach or default under or give rise to a right of early termination under or require any third party consent, authorization or approval by any Person (including any Governmental Authority) that is not an Affiliate of the Company (other than which have already been obtained or that Company reasonably determines would not be burdensome to obtain upon NovaQuest’s reasonable request to obtain), any Applicable Law or contract to which the Company or any of its assets are bound (other than any contract entered into for purposes of contravening or avoiding the Company’s obligations hereunder), including, for the avoidance of doubt, any intercreditor agreement; or
(iv)
would result in adverse tax consequences to the Company or any of its Affiliates.
(e)
For the avoidance of doubt, the security interest granted to NovaQuest pursuant to this Section 4.5(and any perfection, priority or protection thereof) shall be subject to the terms of any [*] executed from time to time after the date hereof, and with respect to any conflict between this Agreement and any [*].
22
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
ARTICLE V
INFORMATION RIGHTS; RECORD KEEPING
5.1
Information Rights.
(a)
In addition to Company’s other reporting and disclosure obligations contained in this Agreement, and, with respect to information Company has the right to receive under the Astellas Agreements and information that Company is provided under the Astellas Agreements, Company shall, and shall cause all other Responsible Parties to, upon NovaQuest’s reasonable request, promptly prepare and provide NovaQuest with reasonable notice and information regarding each of the following matters relating to the Product and to promptly respond to NovaQuest’s reasonable inquiries with respect thereto and promptly provide, upon NovaQuest’s reasonable request, information and documents related to each of the following matters, in each case, to the extent relating to, or that could be reasonably expected to materially affect, the Commercialization of the Product in the Territory:
(i)
general Commercialization overview and updates, including any material issues regarding manufacturing of the Product;
(ii)
finalized briefing packages and minutes from meetings with a Governmental Authority, notifications, letters, and other material communications with a Governmental Authority;
(iii)
material Regulatory Filings, including any NDA;
(iv)
any material actual or anticipated issues with the supply of the Product;
(v)
any matters arising from Patents Covering the Product and other intellectual property rights protecting the Product, including intellectual property rights owned or controlled by Third Parties, that would reasonably be expected to materially and adversely impact the Commercialization of the Product;
(vi)
any decision or anticipated decision to cease marketing, selling, or otherwise Commercializing the Product;
(vii)
receipt of Regulatory Approvals; and
(viii)
each Sales Forecast to be provided pursuant to Section 5.1(b).
Notwithstanding the foregoing, Company may, at its election, deliver the information contemplated herein and therein via disclosures made pursuant to Company’s public reporting requirements, by delivery of summaries, reports, or presentations to NovaQuest, or by providing excerpts of materials presented to the Company’s board of directors or executive leadership team, provided that upon NovaQuest’s reasonable request, Company promptly shall provide
23
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
reasonable access to any material information and documents encompassing the information provided by Company pursuant to this Section 5.1(a).
(b)
To the extent that Company is able to forecast and track, and actually does forecast and track orders for the Product in the Territory, Company will, on an annual basis during the Term and within [*] after approval from the Company’s board of directors, provide NovaQuest with a copy of Company’s good faith forecasted sales of the Product in the Territory for the then-current Fiscal Year (each such Fiscal Year forecast, a “Sales Forecast”). The form and format of the Sales Forecasts shall be as reasonably determined by the Company, provided, however, that each such Sales Forecast shall take into account any forecasts provided by Responsible Parties if such forecast is provided by any Responsible Party. This Section 5.1(b)does not, with respect to obtaining information from Astellas, require Company to take any actions beyond which Company has the right to take under the Astellas Agreements.
(c)
[*], upon NovaQuest’s reasonable advance request, NovaQuest shall be entitled to an update call or meeting (via teleconference or videoconference or at a location reasonably designated by NovaQuest) to discuss (i) the Quarterly Reports and the Payment Reports, (ii) [*], the progress of Commercialization efforts with respect to the Product in the Territory, (iii) [*], the status and the historical and potential performance of the Product in the Territory, (iv) [*], any regulatory developments with respect to any Product in the Territory; and (v) such other matters that the Parties mutually deem reasonably appropriate.
5.2
Company’s Record Keeping; NovaQuest’s Audit Rights.
(a)
Records. Company shall, and shall ensure that the Responsible Parties shall, consistent with GAAP or IFRS, as applicable, keep and maintain for a period of at least [*] from the end of any Fiscal Quarter (except as otherwise provided herein) accounts and records of all data reasonably required to verify (and, with respect to periods prior to the A&R Effective Date, including data relating to Astellas Japan Revenue to the extent necessary to verify Revenue Interest Payments attributable to such periods):
(i)
information required to be provided to NovaQuest under this Agreement, including pursuant to Section 5.1; and
(ii)
(A) the gross amount received by any Responsible Party from Third Parties for sales of the Product, and (B) the calculation of the Revenue Interest Payments.
Company’s and the Responsible Parties’ recordkeeping obligations under this Section 5.2shall survive the termination of this Agreement until the date that is [*] following the last day on which a payment is due under this Agreement (the “Recordkeeping Period”).
(b)
Audit. From the Effective Date until the expiration of the Recordkeeping Period, upon prior written notice to Company: (i) NovaQuest shall have the right to review and audit, through an independent certified public accountant selected by NovaQuest and reasonably satisfactory to Company, those accounts and records of Company as NovaQuest determines is reasonably necessary to verify Company’s and Responsible Parties’ compliance with this
24
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
Agreement; and (ii) Company shall, upon the reasonable request of NovaQuest, [*] review and audit each Responsible Party, through an independent certified public accountant reasonably approved by NovaQuest, those accounts and records of each such Responsible Party as NovaQuest determines is reasonably necessary to verify such Responsible Party’s compliance with this Agreement. Such review and audits shall occur during normal business hours and no more than once per Fiscal Year, provided that NovaQuest shall be entitled to conduct a reasonable number of follow-up reviews and audits if NovaQuest finds that Company or a Responsible Party is not in material compliance with this Agreement. In addition, Company shall, upon reasonable request by NovaQuest (which request NovaQuest shall be permitted to make one time every [*], promptly exercise its audit rights pursuant to the Section of the Astellas EMEA Agreement titled “Reporting and Audit Rights,” to the extent necessary to verify the calculations of Astellas EMEA Revenue or Astellas Other Revenue, and shall furnish the results of such audit to NovaQuest. With respect to any Replacement Agreement entered into by Company that would reasonably be expected to generate Replacement Net Sales Revenue or Replacement Other Revenue, Company shall use reasonable efforts to ensure that such Replacement Agreement grants Company audit rights which are substantially similar in all material respects to Company’s audit rights pursuant to the section of the Astellas EMEA Agreement titled “Reporting and Audit Rights.” With respect to any such Replacement Agreement described in the foregoing sentence, Company shall, upon request by NovaQuest (which request NovaQuest shall be permitted to make one time every [*], promptly exercise its audit rights to the extent necessary to verify the calculations of Replacement Net Sales Revenue or Replacement Other Revenue and shall furnish the results of such audit to NovaQuest. NovaQuest shall be solely responsible for all of the expenses of any audit conducted pursuant to this Section 5.2(b), unless the independent certified public accountant’s report shows, in respect of any Fiscal Year then being reviewed, an underpayment of amounts due to NovaQuest hereunder for such Fiscal Year by more than [*], in which case Company shall be responsible for the reasonable expenses incurred by NovaQuest for the independent certified public accountant’s services. If the report shows an underpayment of amounts due to NovaQuest hereunder, then Company will pay NovaQuest an amount equal to such underpayment, plus interest on such amounts in accordance with Section 4.4, within [*] after receipt of notice of such underpayment and copy of the relevant portion of the audit report.
5.3
Notice of Certain Events. Company will notify NovaQuest in writing with respect to the following matters promptly upon Company’s Knowledge thereof (and Company shall be responsible for ensuring that each Responsible Party notifies Company of such matters upon such Responsible Party becoming aware thereof), in each case, to the extent relating to the Commercialization of the Product in the Territory:
(a)
Company’s or any other Responsible Party’s submission of a material Regulatory Filing for the Product, including any NDA;
(b)
Company’s or any other Responsible Party’s receipt of Regulatory Approval for the Product;
(c)
the occurrence of any Material Adverse Effect;
25
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
(d)
any decision by Company or any other Responsible Party to cease the Commercialization of the Product in the Territory;
(e)
the actual or written threat of revocation, withdrawal, suspension, cancellation, termination, or material modification of any approvals or authorizations, including any Regulatory Approval, from any Governmental Authority with respect to the Product in the Territory;
(f)
Company’s or, to the Knowledge of Company, any other Responsible Party’s being debarred, excluded, suspended, or otherwise ineligible to participate in government health care programs;
(g)
Company’s or, to the Knowledge of Company, any other Responsible Party’s becoming a party to a settlement, consent, or similar agreement with any Governmental Authority regarding the Product in the Territory;
(h)
Company’s or, to the Knowledge of Company, any other Responsible Party’s being charged with, or convicted of, violating any Applicable Law regarding the Product in the Territory;
(i)
any recall, suspension, market withdrawal, seizure, warning letter, other written communication asserting lack of compliance with any Applicable Law in any material respect, or any serious adverse event in each case, with respect to the Product in the Territory; and
(j)
any clinical trial of the Product being suspended, put on hold, or terminated prior to completion as a result of any action by a Governmental Authority, or as a result of a Responsible Party’s voluntary decision in the Territory; and
(k)
the receipt by Company or any other Responsible Party of any adverse written notice from any Governmental Authority regarding the approvability or approval of the Product in the Territory.
(l)
Any notice provided pursuant to this Section 5.3shall include a reasonably detailed description of the event giving rise to the requirement to provide such notice, along with complete copies of all material documentation related thereto unless prohibited by Applicable Law.
Notwithstanding the foregoing, Company may, at its election, deliver the information contemplated herein and therein via disclosures made pursuant to Company’s public reporting requirements, by delivery of summaries, reports, or presentations to NovaQuest, or by providing excerpts of materials presented to Company’s board of directors or executive leadership team.
5.4
ESG Questionnaires. The Company will provide, to the Knowledge of Company and solely as permitted by Applicable Law, true and complete responses to any ESG Questionnaires submitted to Company by NovaQuest no more than once per each Fiscal Year during the Term. For the purposes of this Section 5.4and this Agreement, “ESG Questionnaires” means any
26
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
questionnaire, survey, request for information, or other similar inquiry, relating to environmental, social, or governance issues and Company’s policies and practices in connection therewith.
5.5
[Reserved].
ARTICLE VI
CONFIDENTIAL INFORMATION
6.1
Definition of Confidential Information.
(a)
For purposes of this Agreement, the term “Confidential Information” of a Party means the terms of this Agreement and any information or materials furnished by or on behalf of such Party or its Affiliates to another Party or its Affiliates pursuant to this Agreement or learned through observation during visit(s) to any facility of the Party or its Affiliates.
(b)
Notwithstanding Section 6.1(a), the term “Confidential Information” shall not include information that:
(i)
was already known to the receiving Party, other than under a legal, contractual, or fiduciary obligation of confidentiality to or for the benefit of the disclosing Party, at the time it was disclosed to or learned by the receiving Party hereunder;
(ii)
was generally available to the public at the time it was disclosed to or learned by the receiving Party hereunder;
(iii)
became generally available to the public after it was disclosed to or learned by the receiving Party hereunder, other than through any act or omission of the receiving Party or its Affiliates or representatives in breach of this Agreement;
(iv)
was lawfully disclosed to the receiving Party, after it was disclosed to or learned by the receiving Party hereunder, by a Third Party that, to the receiving Party’s knowledge, was not bound by any legal, contractual, or fiduciary obligation of confidentiality to or for the benefit of the disclosing Party with respect to such information; or
(v)
is independently developed by the receiving Party without the benefit or use of the Confidential Information of the disclosing Party.
6.2
Obligations. Except as authorized in this Agreement or except upon obtaining the other Party’s prior written consent, each Party agrees that for the Term and for [*] thereafter, it will:
(a)
maintain in confidence, and not disclose to any Person, the other Party’s Confidential Information;
(b)
not use the other Party’s Confidential Information for any purpose, except for performing its obligations and exercising its rights and remedies under this Agreement; and
27
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
(c)
protect the other Party’s Confidential Information in its possession by using substantially the same or higher degree of care that it uses to protect its own Confidential Information (but no less than a reasonable degree of care).
Notwithstanding anything to the contrary in this Agreement, a Party is entitled to seek injunctive relief to restrain the breach or threatened breach by the other Party of this ARTICLE VIwithout having to prove actual damages or threatened irreparable harm or post any bond. Such injunctive relief will be in addition to any rights and remedies available to the aggrieved Party at law, in equity, and under this Agreement for such breach or threatened breach.
6.3
Permitted Disclosures.
(a)
Permitted Persons. A Party may disclose the other Party’s Confidential Information, without the other Party’s prior written permission, to:
(i)
its Affiliates and its and its Affiliates’ limited partners, members, managers, directors and individuals or bodies responsible for governance of receiving Party (including, with respect to NovaQuest, NovaQuest’s investment committee and limited partner advisory committee), banks and other actual or potential financing sources, and actual or potential permitted assignees, purchasers, transferees, or successors-in-interest under Sections 8.2or 11.6or its or their employees, agents, consultants, attorneys or accountants, in each case, who need to know such Confidential Information (including to provide financing to receiving Party, to assist receiving Party in evaluating or monitoring receiving Party’s interests in the transactions contemplated hereby, or in fulfilling its obligations or exploiting its rights hereunder (or to determine their interest in providing such financing or assistance)) and who are, prior to receiving such disclosure, bound by customary contractual or professional confidentiality and non-use obligations;
(ii)
other Persons who are (A) investors or potential investors (or advisors or fiduciaries (including trustees) or underwriters or placement agents to such Persons) in connection with a private placement or other equity, debt, or other investment or potential investment transaction in or with receiving Party (including, with respect to NovaQuest, an investment or potential investment in or with NovaQuest or a NovaQuest Affiliate), who need to know such Confidential Information in connection with making or monitoring such equity, debt, or other investment or potential investment transaction, or (B) in the case of NovaQuest, potential investment targets (provided that (1) for the purpose of this Section 6.3(a)(ii), receiving Party may disclose only Confidential Information of disclosing Party pertinent to the investment or potential investment transaction and may make such disclosures only in anticipation, and during the period, of such investment or potential investment transaction, and (2) for the purpose of clause (B) of this Section 6.3(a)(ii), NovaQuest may disclose the identity of Company, the Product that is the subject of this Agreement, and the fact that this Agreement provides for the Investor Return Payments) provided that in the case of clauses (A) and (B) of this Section 6.3(a)(ii), such Persons are, prior to receiving such disclosure, bound by customary contractual or professional obligations of confidentiality, nondisclosure, and nonuse; and
28
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
(iii)
officers, employees, or advisors of any Governmental Authorities for the purpose of submitting Regulatory Filings for the Product and obtaining or maintaining Regulatory Approval, or in connection with any routine examination of a Party by a Governmental Authority.
[*].
(b)
Legally Required. A Party may disclose the other Party’s Confidential Information, without the other Party’s prior written permission, to any Person to the extent such disclosure is necessary to comply with Applicable Law, applicable stock exchange requirements, or an order or subpoena from a court of competent jurisdiction. In the case of any compelled disclosure, the compelled Party, to the extent legally permissible, shall give reasonable advance notice to the other Party of such disclosure and, at such other Party’s reasonable request and expense, the compelled Party shall use its reasonable efforts to secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise). However, if a Party receives a request from an authorized representative of a U.S. or foreign tax or financial reporting authority (including the U.S. Securities and Exchange Commission) for a copy of this Agreement, then that Party may provide a copy of this Agreement to such authority representative without advance notice to, or the permission or cooperation of, the other Party, but the disclosing Party shall notify the other Party of the disclosure as soon as reasonably practical.
(c)
NovaQuest Consent. Notwithstanding anything to the contrary in this Section 6.3, Company shall not, and Company agrees to ensure that Responsible Parties shall not, without the prior written consent of NovaQuest (not to be unreasonably, withheld, conditioned or delayed), disclose to a Third Party any: [*].
6.4
Terms of Agreement. The Parties agree that they will each treat the existence, contents and terms of this Agreement as confidential, and neither Party shall make any press release or other disclosure to the general public that discloses or otherwise concerns this Agreement or any terms hereof, without the prior written consent of the other Party (not to be unreasonably, withheld, conditioned or delayed), except to the extent permitted under Section 6.3or as otherwise permitted in accordance with this Section 6.4or Section 6.5. Notwithstanding anything to the contrary in this Agreement, NovaQuest acknowledges and agrees that it will be necessary for Company to file this Agreement with the SEC and to make other public disclosures regarding the terms of this Agreement and payments made under this Agreement in its reports filed with the SEC and consents to such public filing and the making of such public disclosures, and Company agrees that it will provide NovaQuest a reasonable opportunity to review and comment on any proposed redactions to the copy of this Agreement to be filed with the SEC, as well as on such other public disclosures made by Company relating to NovaQuest or this Agreement or the transactions contemplated thereby, which comments Company shall consider in good faith, provided that Company shall not be required to provide NovaQuest the opportunity to review and comment on any disclosure substantively identical to any disclosure previously reviewed and commented upon by NovaQuest. For purposes of clarity, Company shall not be required to provide NovaQuest the opportunity to review and comment on any disclosure substantively
29
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
identical to any disclosure previously reviewed and commented upon by NovaQuest and each Party is free to republish or discuss with Third Parties the information regarding the Agreement and the Parties’ relationship disclosed in such securities filings and any other authorized public announcements. For the avoidance of doubt, any consent or approval given by a Party with respect to any press release or general public disclosure under or in connection with Section 6.4 of the Original Agreement prior to the A&R Effective Date shall not be deemed to constitute a consent or approval for purposes of this Section 6.4.
6.5
Use of Names. Neither Party shall mention or otherwise use the name, insignia, symbol, trademark, trade name or logotype of the other Party or its Affiliates (or any abbreviation or adaptation thereof) in any publication, press release, publicly available promotional material, or other form of publicity without the prior written approval of such other Party in each instance. Notwithstanding the foregoing, the restrictions imposed by this Section 6.5shall not prohibit a Party from making any disclosure identifying any such Person to the extent required by Applicable Law or the rules of a stock exchange on which the securities of the disclosing Party are listed (or to which an application for listing has been submitted) or to the extent that such information is already public information. Further, notwithstanding the foregoing except for disclosures required by Applicable Law or the rules of a stock exchange or to the extent such information is already public information, the Parties agree that each Party shall have the right to publicly disclose the existence of this Agreement as a revenue interest financing agreement with revenue interest payments, Company’s prepayment option, the name of the Parties, the name and a description of the Product, and the amount of the Investment Amount and the Repurchase Price.
ARTICLE VII
REPRESENTATIONS AND WARRANTIES; LIMITATION OF LIABILITY
7.1
Company’s Representations and Warranties. Except as set forth in the applicable Schedules attached hereto, Company represented and warranted to NovaQuest previously on the Effective Date (but not on any other date and not on the A&R Effective Date, except as expressly set forth below) as follows:
(a)
Organization. As of the A&R Effective Date, Company is a corporation duly incorporated, validly existing, and in good standing under the laws of the State of Delaware and is qualified to do business and legally permitted to perform its obligations under this Agreement in each jurisdiction where failure to be so qualified could result in a Material Adverse Effect.
(b)
Authorization. As of the A&R Effective Date, Company has all necessary corporate or other power, right, and authority to carry on its business as it is presently carried on by Company and as contemplated by this Agreement, to enter into, to execute and deliver this Agreement, and to perform all of the covenants, agreements, and obligations to be performed by Company hereunder. As of the A&R Effective Date, this Agreement has been duly executed and delivered by Company and, when executed and delivered by NovaQuest, constitutes Company’s valid and binding obligation, enforceable against Company in accordance with its terms, subject
30
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
to bankruptcy, insolvency, reorganization, or similar laws affecting the rights of creditors generally and equitable principles.
(c)
No Conflicts. As of the A&R Effective Date, the execution and delivery of this Agreement by Company and the performance by Company of its obligations hereunder does not and will not: (i) violate any provision of the organizational documents of Company; (ii) conflict with or violate any Applicable Law that applies to Company or its assets or properties; (iii) require any permit, authorization, consent, approval, exemption, or other action by, notice to, or filing with any entity or Governmental Authority (other than as expressly contemplated hereby); (iv) violate, conflict with, result in a material breach of, or constitute (with or without notice or lapse of time or both) a material default under, or an event that would give rise to any right of notice, modification, acceleration, payment, cancellation, or termination under, or in any manner release any party thereto from any obligation under, any permit or contract to which Company or any Affiliate of Company is a party or by which any of its properties or assets are bound; or (v) except as provided in Section 4.5, result in the creation or imposition of any Encumbrance on any part of the Collateral of Company (other than Permitted Encumbrances)[*].
(d)
No Consent. As of the A&R Effective Date, except for (i) any consents required to be provided from Astellas under the Astellas Agreements, (ii) any filings necessary to perfect the security interest granted in favor of NovaQuest under Section 4.5and (iii) other consents which have already been obtained, no other consent, approval, license, order, authorization, registration, declaration, or filing with or of any Person, other than Regulatory Approvals required with respect to the Product, is required by Company in connection with the execution and delivery by Company of this Agreement, the performance by Company of its obligations under this Agreement, or the consummation of any of the transactions contemplated hereby[*].
(e)
Product Property. A list of the Patents owned or controlled by Company that Cover the Product in the Territory as currently Commercialized is set forth in Schedule 7.1(e)(the “Product Patents”). To the Knowledge of Company, all of the Product Patents are in full force and effect and have not lapsed, expired, or otherwise terminated. Except as set forth in Schedule 7.1(e), no Person has made a written claim to Company or, to the Knowledge of Company, to any other Party, to be an inventor under any of the Product Patents who is not a named inventor thereof. Company has good and valid title to and solely owns all right, title, and interest in and to the Product Patents subject to Permitted Encumbrances and the License. To Company’s Knowledge, the Product Patents are all of the Patents reasonably necessary for the Commercialization of the Product in Territory as currently Commercialized or contemplated to be Commercialized. [*].
(f)
Litigation. Except as set forth in Schedule 7.1(f), there is no action, suit, claim, proceeding, interference, reexamination, opposition, inter partes or post-grant review, or investigation pending or, to the Knowledge of Company, threatened against Company, any other Responsible Party, or any of its or their licensors, at law or in equity, in an arbitration proceeding to which Company, any other Responsible Party, or any of its or their licensors is a party, or Governmental Authority inquiry pending or, to the Knowledge of Company, threatened against Company, any other Responsible Party, or any of its or their licensors, that, in each case, if
31
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
adversely determined, would: (i) question or defeat the validity or enforceability of any Product IP Rights; (ii) prevent, interfere with, or delay the consummation of the transactions contemplated by this Agreement; (iii) otherwise adversely affect any Product IP Rights or NovaQuest’s rights under this Agreement; or (iv) have, or reasonably be expected to result in, a Material Adverse Effect.
(g)
Infringement and Intellectual Property. As of the A&R Effective Date, to the Knowledge of Company, the making, use, sale, offer for sale, or import of the Product as currently Commercialized or contemplated to be Commercialized by any Responsible Party, Licensees, or sublicensees in the Territory does not, and will not, during the Term, infringe any issued Patent of any Third Party or misappropriate or make any unauthorized use of any other intellectual property or proprietary asset of any Third Party. To the Knowledge of Company, the Product Patents are, or will be upon issuance, valid and enforceable and no Third Party is infringing, misappropriating, or making any unauthorized use of a Product Patent or Product Know-How. None of the Product Patents or Product Know-How is subject to any outstanding decree, order, judgment, or stipulation restricting in any manner the use or licensing thereof by Company.
(h)
Material Contracts. As of the A&R Effective Date, [*] to which Company or its Affiliates are a party are listed in Schedule 7.1(h)and are enforceable and in full force and effect, except as such enforceability may be limited due to applicable Bankruptcy Laws affecting the enforcement of creditors’ rights generally, and general principles of equity. Company has provided correct and complete copies of all such Material Contracts to NovaQuest, and such copies remain correct and complete as of the A&R Effective Date. As of the A&R Effective Date, each Responsible Party is in compliance with and has not materially breached, violated, or defaulted under, or received written notice that it has materially breached, violated, or defaulted under any of the terms or conditions of any such Material Contract. As of the A&R Effective Date, Company is not aware of any event that has occurred or circumstance or condition that exists that would, or would reasonably be expected to, constitute such a breach, violation, or default with the lapse of time, giving of notice, or both. To the Knowledge of Company, as of the A&R Effective Date, the counterparty of each Material Contract is in compliance in all material respects with the terms and conditions of such Material Contract. Except as set forth in Schedule 7.1(h), as of the A&R Effective Date, Company has not granted an Encumbrance on any of its Product IP Rights, on the Revenue Interests, or on any of Company’s payments to NovaQuest under this Agreement (in each case, solely to the extent constituting Collateral), except Permitted Encumbrances.
(i)
Certain Regulatory Matters.
(i)
To the Company’s Knowledge, a Responsible Party holds all or is seeking the applicable approvals and authorizations from Governmental Authorities necessary for Company or, to the Knowledge of Company, such Responsible Party to conduct its business in the manner in which such business is being conducted and as contemplated hereunder with respect to the Product in the Territory, including the manufacture, testing, and Commercialization of the Product. To the Knowledge of the Company, the countries in which a
32
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
Responsible Party holds an applicable approval and authorization for the Product in the Territory is as set forth on Schedule 7.1(i)and all such issued approvals and authorizations are in good standing and in full force and effect. Company or, to the Knowledge of Company, a Responsible Party has not received any written notice or any other communication from any Governmental Authority regarding any actual or possible revocation, withdrawal, suspension, cancellation, termination, or material modification of any such issued or pending approvals or authorizations for the Product in the Territory.
(ii)
Company has not, and, to the Knowledge of Company, no other Responsible Party has, with respect to the Product in the Territory, knowingly made any untrue statement of a material fact or fraudulent statement to any Governmental Authority, failed to disclose a material fact required to be disclosed to any Governmental Authority, or committed an act, made a statement or failed to make a statement, that provides or could reasonably be expected to provide a basis for the FDA or other Governmental Authority to invoke the FDA’s policy respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” set forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar policy of any other Governmental Authority.
(iii)
Company is not and has never been, and, to the Knowledge of Company, no Responsible Party is or has ever been: (A) debarred by a Governmental Authority; (B) a party to a settlement agreement, consent decree, or similar agreement with a Governmental Authority regarding the Product in the Territory; or (C) charged with, or convicted of, violating Applicable Law regarding the Product in the Territory.
(iv)
To the Knowledge of Company, the Product has not been the subject of or subject to (as applicable) any recall, suspension, market withdrawal, seizure, warning letter, other written communication asserting lack of compliance with any Applicable Law in any material respect in the Territory. No clinical trial of the Product in the Territory has been suspended, put on hold, or terminated prior to completion as a result of any action by any Governmental Authority or voluntarily.
(v)
Neither Company nor its Affiliates have, and, to the Knowledge of Company, no other Responsible Party or exclusive licensor of any Product Patent, has received any adverse written notice from any Governmental Authority regarding the approvability or approval of the Product in the Territory.
(j)
Financial Condition. All financial statements for Company delivered to NovaQuest fairly present, in conformity with GAAP or IFRS, as applicable, in all material respects Company’s financial condition and Company’s results of operations. There has not been any material deterioration in Company’s financial condition since the date of the most recent financial statements delivered to NovaQuest.
(k)
Supply. The Company has on hand or has made adequate provisions to secure sufficient quantities of Product to meet its obligations under the Astellas Agreements. The Company has on hand or has made adequate provisions to secure sufficient quantities of Product to support the Commercialization of the Product in the Territory.
33
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
(l)
Lien Representations and Warranties. As of the A&R Effective Date, the Company’s exact legal name is “Kyntra Bio, Inc.” (formerly known as “FibroGen, Inc.”). As of the A&R Effective Date, the Company is, and has been since its incorporation, incorporated in the State of Delaware.
(m)
Taxes. Company and its subsidiaries have: (i) filed all federal and state income Tax returns and other material Tax returns that they are required to file and (ii) duly paid all federal and state income Taxes and other material Taxes or installments thereof that they are required to pay, except Taxes being contested in good faith by appropriate proceedings and for which Company and its subsidiaries maintain adequate reserves in accordance with GAAP.; With respect to Company and its subsidiaries, there are no proposed or pending Tax assessments, deficiencies, audits, or other proceedings that have had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.
(n)
Brokers’ Fees. Except for Morgan Stanley & Co. LLC, there is no investment banker, broker, finder, financial advisor, or other intermediary who has been retained by or is authorized to act on behalf of Company who might be entitled to any fee or commission in connection with the transactions contemplated by the Transaction Documents.
(o)
Ownership. As of the A&R Effective Date, Company is the exclusive owner of the entire right, title (legal and equitable), and interest in, to, and under the Revenue Interests, and has good and valid title thereto.
(p)
Solvency. Upon consummation of the transactions contemplated by the Transaction Documents and the application of the proceeds therefrom: (i) the fair saleable value of Company’s assets (on a consolidated basis) will be greater than the sum of its Indebtedness, liabilities and other obligations, including contingent liabilities; (ii) the present fair saleable value of Company’s assets (on a consolidated basis) will be greater than the amount that would be required to pay its probable liabilities on its existing Indebtedness, liabilities and other obligations, including contingent liabilities, as they become absolute and matured; (iii) Company will be able to realize upon its assets (on a consolidated basis) and pay its Indebtedness, liabilities and other obligations, including contingent obligations, as they mature; (iv) Company (on a consolidated basis) will not be rendered insolvent (within the meaning of any applicable law or otherwise), will not have unreasonably small capital with which to engage in its business and will not be unable to pay its Indebtedness as it matures; and (v) Company will not have become subject to any Voluntary Bankruptcy or Involuntary Bankruptcy. No step has been taken by Company or, to the Knowledge of Company, any other Person, to make Company subject to a Voluntary Bankruptcy or Involuntary Bankruptcy.
(q)
Full Disclosure. With respect to the Product in the Territory, Company has previously delivered to NovaQuest true and complete copies of all agreements, contracts, documents, or other information referred to in this Agreement or that have been requested by NovaQuest, in each case, that has not been publicly disclosed by the Company. No representation or warranty or other statement made by Company in this Agreement, the Exhibits, the Schedules, any supplements, attachments, or annexes to the Exhibits or Schedules, or any certificates delivered in connection with the transactions contemplated in this Agreement
34
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
contains any untrue statement or omits to state a material fact necessary to make any of them, in light of the circumstances in which it was made, not misleading. To the Knowledge of Company, there is no fact, event, or condition that has specific application to Company and that materially adversely affects the Product that has not been set forth in this Agreement, the Exhibits, and the Schedules hereto.
(r)
Applicable Astellas Agreements and Product IP Rights. As of the A&R Effective Date, the Astellas EMEA Agreement and the Astellas EU Supply Agreement specifically referenced in Schedule 7.1(h) have not been amended, modified, supplemented or waived since the Effective Date and the Product IP Rights have not been amended in a manner that would reasonably be expected to materially adversely affect the amount of any Revenue Interest Payments that otherwise would have been payable to NovaQuest in the absence of any such amendment since the Effective Date.
7.2
NovaQuest’s Representations and Warranties. NovaQuest represents, warrants, and covenants to Company as of the A&R Effective Date as follows:
(a)
Organization. NovaQuest is a Delaware limited partnership duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization.
(b)
Authorization. NovaQuest has all necessary power, right, and authority to carry on its business as it is presently carried on by NovaQuest, to enter into, execute, and deliver this Agreement and perform all of the covenants, agreements, and obligations to be performed by NovaQuest hereunder. This Agreement has been duly executed and delivered by NovaQuest and constitutes, when executed and delivered by Company, NovaQuest’s valid and binding obligation, enforceable against NovaQuest in accordance with its terms, subject to bankruptcy, insolvency, reorganization, or similar laws affecting the rights of creditors generally and equitable principles.
(c)
No Conflict. Neither the execution and delivery of this Agreement nor the performance or consummation of it or the transactions contemplated hereby will: (i) conflict with any Applicable Law; (ii) in any material respect, violate, conflict with, result in a material breach of, or constitute a material default under any material contract, agreement, commitment, or instrument to which NovaQuest is a party or by which NovaQuest or any of its assets are bound or committed; or (iii) violate the applicable formation documents for NovaQuest.
(d)
No Consent. No consent, approval, license, order or authorization, registration, declaration, or filing with or of any Person is required by NovaQuest in connection with the execution and delivery by NovaQuest of this Agreement, the performance by it of its obligations under this Agreement, or the consummation by it of any of the transactions contemplated hereby or thereby.
(e)
Litigation. There is no action, suit, claim, proceeding, or investigation pending or, to the knowledge of NovaQuest, which, for the purpose of this Section 7.2(e)means the actual knowledge of [*], threatened against NovaQuest or any of its Affiliates, at law or in equity, in an arbitration proceeding to which NovaQuest or any of its Affiliates is a party, or pursuant to the
35
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
procedures of a Governmental Authority having jurisdiction over NovaQuest or its Affiliates, that, if adversely determined, would: (i) prevent the consummation of the transactions contemplated by this Agreement; or (ii) otherwise materially adversely affect Company’s rights under this Agreement.
(f)
Financing. NovaQuest has the contractual right to call, from amounts contractually committed by its investors, sufficient cash to pay the Investment Amount in accordance with this Agreement. NovaQuest acknowledges that its obligations under this Agreement are not contingent on obtaining financing.
7.3
[*].
ARTICLE VIII
COVENANTS
8.1
Notifications.
(a)
Defaults, Termination and Litigation.
(i)
Company shall promptly upon obtaining Knowledge thereof notify NovaQuest in writing and with reasonable detail of any actual or threatened (or any receipt of notice of any actual or threatened): (A) default or material breach by Company or the counterparty under any Material Contract, (B) default or breach by Company or Astellas under the Astellas Agreements if such default or breach would reasonably be expected to have a material adverse effect on the amount of the Revenue Interest Payments; or [*]. For avoidance of doubt, as this section relates to the Astellas Agreements, such notification shall be limited to information Company has the right to receive under the Astellas Agreements or information of which the Company has Knowledge.
(ii)
Company shall promptly upon obtaining Knowledge thereof notify NovaQuest in writing and with reasonable detail of the actual or threatened commencement of (or receipt of notice of the actual or threatened commencement of) any dispute, claim, suit, litigation, injunction, or arbitration proceeding related to the Product, [*], or a Material Contract, including those disputes, claims, suits, litigation, or arbitration proceedings alleging a Third Party’s infringement or misappropriation of any of the Product IP Rights owned or licensed by a Responsible Party and those alleging a Responsible Party’s (or any of their respective Affiliates’, licensees’, or sublicensees’) infringement or misappropriation of a Third Party’s intellectual property in the making, use, sale, offer for sale, or importation of the Product. Each such notification shall contain a reasonably detailed summary of the event described therein. At the request of NovaQuest, Company shall promptly discuss with NovaQuest, or provide in writing to NovaQuest, full particulars of the applicable matter. For avoidance of doubt, as this section relates to the Astellas Agreements, such notification shall be limited to information Company has the right to receive under the Astellas Agreements or information of which the Company has Knowledge.
36
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
(b)
Intellectual Property Updates. Company shall keep NovaQuest reasonably informed, in accordance with its obligations under ARTICLE V, with regard to all material developments in the status, validity, prosecution efforts, or change thereto, of any of the Product Patents in the Territory owned, licensed, or sublicensed by a Responsible Party, in each case to the extent Company has Knowledge thereof. For avoidance of doubt, as this section relates to the Astellas Agreements, such notification shall be limited to information Company has the right to receive under the Astellas Agreements or information of which the Company has Knowledge.
8.2
No Disposition of Rights.Notwithstanding anything to the contrary herein, but without limiting Company’s obligations under Section 8.6(d), without NovaQuest’s prior written consent (not to be unreasonably, withheld, conditioned or delayed), Company shall not (and Company shall ensure that each of its Affiliates does not) Encumber any: (a) Revenue Interest Payments or (b) Product IP Rights, in each case, solely to the extent constituting Collateral, other than Permitted Encumbrances.
8.3
Event of Default.
(a)
The Company shall notify NovaQuest in writing as soon as possible, and in any event within [*] of the occurrence and continuance of any Event of Default during the Term, identifying the nature of such Event of Default. [*].
(b)
Subject to the terms and conditions of [*], if an Event of Default has occurred and is continuing and [*], NovaQuest may exercise remedies available at law or in equity in respect of the Collateral, including directing Company and its Affiliates to assemble and deliver the Collateral as directed by NovaQuest, notifying any Third Party holding such Collateral (or portion thereof) of NovaQuest’s rights in such Collateral (or portion) and directing such Third Party to transfer such Collateral or make payments in respect thereof to NovaQuest (and Company hereby consents to such transfer or payment); [*]. For the avoidance of doubt, [*], NovaQuest shall have no right to exercise any remedies in respect of the Collateral, and all security interests and Liens granted to NovaQuest hereunder shall be immediately and automatically terminated, released and discharged (and all other actions shall be taken by the applicable Persons) in accordance with Section 4.5(c).
8.4
Change of Control of Company. In the event of a Change of Control of Company, at Company’s option, Company shall either: (a) cause its obligations under this Agreement to be assumed by the Acquiring Party if all of the following conditions have been met (i) NovaQuest has been provided with a true, complete, and accurate copy of the primary definitive agreement (and any ancillary documents reasonably required for a complete understanding thereof) relating to the Change of Control (subject to redaction and omission to the same extent as the publicly-filed version of such agreement), (ii) solely with respect to a Change of Control in which the Acquiring Party is not a Permitted Company, NovaQuest has provided its prior written consent to the Change of Control, which consent may not be unreasonably withheld, conditioned, or delayed, and (iii) the Acquiring Party has agreed in writing, in form and substance reasonably acceptable to NovaQuest, to assume all of Company’s obligations under this Agreement; or (b) elect to pay the then-current Capped Return Amount to NovaQuest in full pursuant to Section 4.1(d); providedthat Company shall have [*] following written notice from NovaQuest to make
37
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
such election and, if Company elects clause (b), to pay the then-current Capped Return Amount; provided, furtherthat, this Section 8.4shall not apply in the event a Change of Control pursuant to subsection (d) of the definition of Change of Control occurs; provided, further, however, that Company shall provide notice promptly upon such occurrence.
8.5
Company IP Obligations. Company shall use [*] to (and shall cause each Responsible Party to):
(a)
prosecute and maintain in full force and effect all Product Patents in the Territory owned or controlled by it on or after the Effective Date and all Regulatory Approvals related to the Productin the Territory;
(b)
maintain, keep in full force and effect, and seek available patent term extensions for any such Product Patents;
(c)
defend any challenge to the validity, patentability, enforceability, or non-infringement of any such Product Patents or any opposition to any such Product Patents;
(d)
if a Third Party is infringing such Product Patents, cause such infringement to cease, including by initiating legal proceedings against any Third-Party infringer as necessary;
(e)
promptly provide NovaQuest with written notice of any (i) action or settlement discussions relating to any alleged, actual, or potential infringement of Product Patents to the extent reasonably necessary to Commercialize the Product in the Territory, and (ii) damages award or settlement with respect thereto; and
(f)
maintain all Product Know-How in confidence.
This Section 8.5does not require Company to take any actions beyond which Company has the right to take under the Astellas Agreements in effect as of the Effective Date.
8.6
Additional Covenants and Agreements of Company.
(a)
Compliance with Law. With respect to the performance of this Agreement and the activities contemplated by this Agreement, Company shall comply, and shall cause each Responsible Party to comply, with all Applicable Laws.
(b)
Noncontravention.Except as set forth in [*] or as otherwise set forth in this Agreement, during the Term, Company shall not grant any right to any Affiliate or Third Party that would conflict with the rights granted to NovaQuest hereunder or enter into any agreement that would impair Company’s ability to perform its obligations under this Agreement.
(c)
Material Contracts and Licenses.Company shall comply with all terms and conditions of, and fulfill all of its obligations under, all of the Material Contracts, except for such noncompliance that would not reasonably be expected to result in a Material Adverse Effect. Company shall use [*] to enforce against the other party(ies) to each Material Contract all
38
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
material terms and conditions thereunder, except where the failure of the other party(ies) to perform would not reasonably be expected to have a Material Adverse Effect. Company shall ensure that all Licenses contain provisions that require the Licensees to notify Company of any Material Adverse Effect and that allow Company to share information pertaining to the Commercialization of the Product to NovaQuest as contemplated by this Agreement. [*].
(d)
Astellas Agreements.
(i)
Without limiting any of Company’s other obligations under this Agreement, Company shall comply with all material terms and conditions of, and fulfill all of its material obligations under, the Astellas EMEA Agreement. Company may not materially amend the Astellas EMEA Agreement, waive any material term thereof, or terminate the Astellas EMEA Agreement without NovaQuest’s prior written consent (not to be unreasonably withheld, conditioned or delayed). Company shall use [*] to enforce all terms of the Astellas EMEA Agreement that, individually or collectively, would reasonably be expected to have a material adverse impact on the amount or timing of any payment to NovaQuest under this Agreement and shall exercise its available rights and remedies at law or in equity in the event of a breach of the Astellas EMEA Agreement with respect to any such terms.
(ii)
Promptly after receiving notice from Astellas, or any other Person (A) terminating an Astellas Agreement (in whole or in part); (B) alleging any breach of or material default under an Astellas Agreement by Company; or (C) asserting the existence of any facts or circumstances that Company reasonably expects to give rise to an Event of Default, Company shall, in each case ((A) through (C)), (X) promptly give a written notice to NovaQuest describing in reasonable detail the relevant breach, default, facts, circumstances, or termination event, including a copy of any written notice received from Astellas or the other relevant Person, and, in the case of any breach, default, or alleged breach or default by Company, describing in reasonable detail any corrective action Company proposes to take, and (Y) in the case of any breach, default, alleged breach or default by Company, use its best efforts to promptly cure such breach or default and give written notice to NovaQuest upon curing such breach or default.
(iii)
Promptly after Company becomes aware of a breach of, default under, or an alleged breach of or default under, an Astellas Agreement by Astellas or any other Person, including, for the avoidance of doubt, by Company or an Affiliate of Company (each, a “Defaulting Party”), or of the existence of any facts, circumstances, or events that, alone or together with other facts, circumstances, or events, Company reasonably expects (with or without the giving of notice or passage of time, or both) to give rise to a breach of or default under an Astellas Agreement by a Defaulting Party or the right to terminate an Astellas Agreement (in whole or in part) by Company, in each case, Company shall promptly (but in any event within [*]) give a written notice to NovaQuest describing in reasonable detail the relevant breach, default, or termination event.
(iv)
Company shall, at NovaQuest’s request and expense, make available its relevant records and personnel to NovaQuest in connection with any prosecution of litigation by Company or NovaQuest against any party to the Astellas Agreements to enforce any of Company’s rights under the Astellas Agreements, and provide reasonable assistance and
39
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
authority to file and bring such litigation, including, if required to bring such litigation, being joined as a party or plaintiff. All reasonable and documented out-of-pocket Third-Party expenses of Company (including reasonable and documented attorneys’ fees) incurred pursuant to this Section 8.6(d)(iv)shall be reimbursed by NovaQuest.
ARTICLE IX
TERM AND TERMINATION
9.1
Term of Agreement. The term of this Agreement shall commence as of the A&R Effective Date and continue until terminated in accordance with this ARTICLE IX(the “Term”).
9.2
Termination.
(a)
Mutual Termination. This Agreement may be terminated by mutual written agreement of Company and NovaQuest.
(b)
Automatic Termination. This Agreement shall immediately and automatically terminate upon the achievement of Investor Return Payment Satisfaction.
(c)
Termination for Event of Default. NovaQuest may terminate this Agreement upon the occurrence and during the continuance of an Event of Default by Company, provided that Company has received written notice from NovaQuest of the occurrence and continuance of such Event of Default, specifying in reasonable detail the particulars of the alleged Event of Default and such Event of Default has not been cured within [*]. NovaQuest will have the right to pursue remedies it may have at law or equity for the occurrence and continuance of such Event of Default, including the right to seek damages from Company.
(d)
Termination for Bankruptcy. NovaQuest may terminate this Agreement in its entirety upon written notice to Company upon the occurrence of a Bankruptcy Event of Default.
9.3
Effects of Termination. Expiration or termination of this Agreement for any reason will not release either Party from any obligation or liability which, at the time of such expiration or termination, has already accrued to the other Party; provided that, notwithstanding anything to the contrary, Company shall never have any obligation or liability under this Agreement, any other Transaction Document or otherwise to NovaQuest, any of its Affiliates or related Persons for an amount greater than the Capped Return Amount, plus any Adjusted Amount; provided, further, that the foregoing shall not limit any liability of either Party resulting from breaches of ARTICLE VI, any non-payment indemnification obligations expressly covered by ARTICLE X, or any liability of either Party arising from fraud or bad faith. Notwithstanding the foregoing or anything else to the contrary, no obligation or liability attributable to any period before the A&R Effective Date shall survive termination or expiration of this Agreement (other than any fraudulent actions of Company or NovaQuest that such Person is unaware of as of the A&R
40
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
Effective Date), all such obligations having been fully and irrevocably satisfied by the Repurchase Price and the Expense Payment paid on the A&R Effective Date.
9.4
Survival. Notwithstanding anything to the contrary contained in this Agreement, Sections 4.1(d)(Capped Return Payoff), 4.1(e)(Capped Return Amount; Termination), 4.3(Taxes; Withholding), 4.4(Interest) and 4.5(c)(release of security interests), this Section 9.4 shall survive any termination of this Agreement or any other Transaction Document until the Capped Return Amount and any accrued, owed, due and unpaid default interest pursuant to Section 4.4have been paid or reduced to zero and all security interests and Liens granted to NovaQuest hereunder have been terminated, released and discharged. In addition, Section 5.2(for the duration of the Recordkeeping Period), ARTICLE VI, ARTICLE X, any liability of either Party arising from fraud or bad faith (for the duration of any applicable statute of limitations), and ARTICLE XIshall survive the termination of this Agreement for any reason.
ARTICLE X
INDEMNIFICATION
10.1
Company’s Indemnification Obligations.Company hereby agrees to indemnify, defend, hold harmless, and reimburse NovaQuest and its Affiliates and their respective managers, directors, officers, employees, agents, and its and their respective successors, heirs, and assigns (collectively, the “NovaQuest Indemnitees”) from and against any losses, costs, claims, damages, Liabilities, or expenses (including reasonable attorneys’ and professional fees and other expenses of litigation) (each, a “Loss” and collectively, “Losses”) actually sustained or incurred by NovaQuest Indemnitees arising out of claims, suits, actions, or demands, in each case brought by a Third Party, or settlements or judgments arising therefrom (including personal injury, products liability, and intellectual property infringement or misappropriation claims) (each a “Third-Party Claim”) as a result or arising out of:
(a)
a Responsible Party’s, or its or their respective agent’s or contractor’s actions or inactions in connection with the Development, promotion, marketing, handling, manufacture, Commercialization, packaging, labeling, storage, distribution, pricing, reimbursement, transport, use, sale, or other disposition of the Product;
(b)
any breach by Company of a representation or warranty of Company contained in this Agreement or in any other agreement between the Parties contemplated by this Agreement or the breach or default by a Responsible Party of any covenant, agreement, or obligation of Company contained in this Agreement or in any other agreement between the Parties contemplated by this Agreement;
(c)
a Responsible Party’s failure to comply with Applicable Law or GxP; or
(d)
[*] recklessness, or intentional wrongful acts or omissions related to this Agreement of a Responsible Party, or contractors or any of their respective directors, employees, or agents.
41
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
10.2
Procedures.
(a)
Notice. If one or more NovaQuest Indemnitees seek indemnification (each, an “Indemnified Party”) under Section 10.1, then NovaQuest shall give prompt written notice to Company of the assertion of any Third‑Party Claim in respect of which indemnity may be sought hereunder. Such notice shall include a description of the Third‑Party Claim, the nature and amount of the applicable Loss, to the extent known at such time, and NovaQuest’s decision with respect to whether Company will assume the defense of the Third‑Party Claim. The failure NovaQuest to notify Company on a timely basis or provide such information as set forth above will not relieve Company of any liability that it may have to an Indemnified Party unless Company demonstrates that Company’s defense of such action is materially prejudiced by NovaQuest’s failure to give such notice and then solely to the extent thereof. The Indemnified Party shall provide Company with complete and correct copies of reasonably relevant papers and official documents received from or on behalf of the Third Party asserting the Third-Party Claim in connection with any Third-Party Claims for which indemnity is sought hereunder and such other information with respect thereto as Company may reasonably request. The Parties shall keep each other reasonably informed of any facts or circumstances that may be of material relevance in connection with the Loss for which indemnification is sought.
(b)
Appointment of Counsel. If NovaQuest elects to have Company assume the defense of any Third‑Party Claim for which indemnification is sought hereunder, then Company will promptly appoint a lead counsel in the defense of such Third‑Party Claim any legal counsel selected by Company that is reasonably acceptable to the Indemnified Party.
(c)
Right to Participate in Defense. Without limiting Section 10.2(b), any Indemnified Party shall be entitled to participate in the defense of such Third‑Party Claim assumed by Company and to employ counsel of its choice for such purpose. However, such employment shall be at the Indemnified Party’s own expense unless: (i) the employment thereof has been specifically authorized by Company in writing; (ii) Company has failed to assume the defense, diligently defend the claim, and employ counsel in accordance with Section 10.2(b)(in which case the Indemnified Party may control the defense); or (iii) the interests of the Indemnified Party and Company with respect to such Third‑Party Claim are sufficiently adverse to prohibit the representation by the same counsel of both Parties under Applicable Laws, ethical rules, or equitable principles, in which case such employment shall be at the expense of Company.
(d)
Settlement. With respect to the defense of any Third‑Party Claim assumed by Company, Company will only have the right to consent to the entry of any judgment or enter into any settlement with respect to such Third‑Party Claim upon the prior written consent of the Indemnified Party (not to be unreasonably, withheld, conditioned or delayed).
(e)
Cooperation. With respect to the defense of any Third‑Party Claim for which indemnification is sought and for which NovaQuest elects the defense thereof to be assumed by Company, the Indemnified Party shall reasonably cooperate in the defense or prosecution thereof, and Company shall reimburse the Indemnified Party for all its reasonable out‑of‑pocket expenses in connection therewith. In the event NovaQuest elects not to have Company assume
42
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
the defense of any Third‑Party Claim for which indemnification is sought, then Company shall cooperate with the Indemnified Party in the defense or prosecution thereof, including by furnishing such records, information, and testimony, providing such witnesses and attending such conferences, discovery proceedings, hearings, trials, and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the Indemnified Party to, and reasonable retention by Company of, records and information that are reasonably relevant to such Third‑Party Claim, and making Company employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder.
(f)
NovaQuest Indemnified Party’s Defense of Third‑Party Claims. If either: (i) Company fails to timely (and in any event [*] assume and diligently conduct the defense of any Third‑Party Claim upon NovaQuest’s election pursuant to Section 10.2(a); or (ii) NovaQuest elects not to have Company assume the defense of a Third‑Party Claim, then the Indemnified Party may assume the defense of, and settle, such Third‑Party Claim with counsel of its own choice and on such terms as it deems appropriate, without any obligation to obtain the consent of Company, at Company’s expense.
10.3
Limitations. The Company’s obligations pursuant to this ARTICLE X shall not apply to the extent such Third-Party Claims result from gross negligence or willful misconduct by any of the Indemnified Parties.
ARTICLE XI
MISCELLANEOUS
11.1
Governing Law; Waiver of Jury Trial. This Agreement shall be governed by and construed, interpreted, and enforced in accordance with the laws of the State of New York, as applied to agreements executed and performed entirely in the State of New York, without giving effect to the principles of conflicts of law thereof. EACH PARTY IRREVOCABLY WAIVES ANY RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING IN CONNECTION WITH OR RELATING TO THIS AGREEMENT OR ANY AGREEMENT ENTERED INTO PURSUANT HERETO AND AGREES THAT ANY SUCH SUIT, ACTION, OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY.
11.2
Dispute Resolution.
(a)
Subject to Section 11.3, prior to the initiation of any Arbitration between the Parties, any dispute, controversy, or claim arising under, out of, or in connection with this Agreement, including any subsequent amendments (a “Dispute”) shall be first discussed in good faith between the Parties’ Senior Officers. Either Party shall have the right to refer a Dispute to the Parties’ Senior Officers for attempted resolution by sending a written notice to the other Party setting forth in reasonable detail the nature of the Dispute (the “Dispute Notice”). If either Party provides a Dispute Notice, then the Senior Officer (or his or her designee) from each Party shall, by phone or in-person, discuss the Dispute in good faith, commencing within [*] after the
43
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
delivery of the Dispute Notice and continuing until at least [*] after the delivery of the Dispute Notice.
(b)
If the two Senior Officers (or their designees) have not reached a mutually acceptable resolution to the Dispute within [*] after the delivery of the Dispute Notice, then either Party may submit the Dispute to arbitration by delivering a written notice to the other Party (an “Arbitration Notice”), and the Dispute shall be resolved by final, binding arbitration conducted in accordance with the then-current Commercial Rules (the “AAA Rules”) of the American Arbitration Association or any successor entity (the “AAA”) including the Procedures for Large, Complex Commercial Disputes (including, as appropriate, the Optional Rules for Emergency Measures of Protection), as amended from time to time, except as provided in this Section 11.2(“Arbitration”).
(c)
Selection of Arbitrators. The Arbitration tribunal shall consist of three (3) arbitrators, who shall be selected as follows: (i) [*] shall be selected by Company; (ii) [*] shall be selected by NovaQuest; and (iii) [*] shall be selected by the [*] (each such arbitrator, an “Arbitrator”). Each of the Arbitrators shall have prior experience in connection with the biopharmaceutical industry, or shall be a retired judge. No Arbitrator shall be a current or former employee, shareholder, officer, or director of, or consultant, or advisor to, or other representative of, either Party. [*].
(d)
Venue and Language. The venue of the Arbitration shall be New York, New York, USA. The Arbitration shall be conducted in English, and all foreign language documents shall be submitted in the original language and shall be accompanied by a certified translation into English.
(e)
Time Periods. The Arbitration shall be conducted expeditiously and efficiently, and absent good cause shown as determined by the Arbitrators, the Arbitrators shall conduct any evidentiary hearing within [*] of confirmation of the panel of Arbitrators. Upon the written mutual agreement of both Parties, any time period specified in this Section 11.2or the [*] shall be extended or accelerated according to the Parties’ written mutual agreement. The Arbitrators shall take into account both the desirability of making discovery efficient and cost-effective and the needs of the Parties for an understanding of any legitimate issue raised in the Arbitration. The Arbitrators shall, upon the request of one or both parties, permit the exchange of documents relevant to the claims and defenses raised in the Arbitration. Unless the Parties mutually agree, no depositions or other discovery devices shall be permitted, absent extraordinary circumstances as determined by the Arbitrators.
(f)
Consolidation of Disputes. In order to facilitate the comprehensive resolution of related disputes, and upon request of any Party to the Arbitration proceeding, the Arbitrators may consolidate the Arbitration proceeding with any other Arbitration proceeding relating to this Agreement. The Arbitrators shall not consolidate such Arbitrations unless they determine that: (i) there are issues of fact or law common to the proceedings so that a consolidated proceeding would be more efficient than separate proceedings; and (ii) no Party would be prejudiced as a result of such consolidation through undue delay or otherwise. The Arbitrators shall have jurisdiction to decide matters of arbitrability.
44
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
(g)
Costs. The costs of the Arbitration, including reasonable fees plus expenses to be paid to the Arbitrator(s) and the reasonable out-of-pocket costs (including the costs incurred for translation of the documents into English, reasonable attorneys’ and expert witness fees, and reasonable travel expenses) of the prevailing Party shall be borne by: (i) the losing Party, if the Arbitrator(s) rule in favor of one Party on all disputed issues in the Arbitration; and (ii) the Parties, as allocated in writing by the Arbitrator(s) in a manner with a reasonable relationship to the outcome of the Arbitration, if the Arbitrator(s) rule in favor of one Party with respect to some issues and in favor of the other Party with respect to other issues and, in either case ((i) or (ii)), paid within [*] from the final decision by the Arbitrator.
(h)
Decision to be Binding. The Arbitrators shall render a reasoned arbitral award. The award by the Arbitrators shall be final and binding on the Parties, non-reviewable and non-appealable, and judgment upon any arbitral award may be entered and enforced by any court or other judicial authority of competent jurisdiction. The Parties’ agreement to arbitrate, and any arbitral award, shall be enforced under the Federal Arbitration Act.
(i)
Confidentiality. All Disputes under this Agreement shall be kept confidential. All settlement negotiations, proceedings, and any award and any information obtained from the other Party in connection with the Arbitration shall be deemed Confidential Information subject to ARTICLE VI, provided that the Parties further agree that such Confidential Information may be disclosed to the extent necessary to enforce any award or enforce this Agreement to arbitrate; provided that either Party may disclose such settlement information if required by the U.S. Securities and Exchange Commission, and such disclosing Party shall use its reasonable efforts to secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise) or with respect to any filing required by a securities agency, the Parties agree to use reasonable efforts to provide the other with a copy of any filing required by a securities agency that will be made publicly available regarding the Agreement or its terms to review prior to filing and to consider any comments of the other Party in good faith, and to the extent either Party is required to file or disclose this Agreement with a securities agency, if the Agreement may become publicly available, such Party shall consider in good faith the other Party’s comments with respect to confidential treatment of the Agreement’s terms and shall redact the Agreement in a manner allowed by the securities agency to protect sensitive terms, and shall be permitted to file the Agreement, as so redacted, with the securities agency.
11.3
Equitable Relief. Each of the Parties hereto acknowledges that the other Party may have no adequate remedy at law if it fails to perform any of its obligations under ARTICLE VIof this Agreement. In such event each of the Parties agrees that the other Party shall have the right, in addition to any other rights it may have (whether at law or in equity), to pursue equitable remedies such as injunction and specific performance for the breach or threatened breach of any provision of such ARTICLE VIfrom any court of competent jurisdiction.
11.4
Expenses. Simultaneously with its payment of the Repurchase Price, Company shall pay NovaQuest for NovaQuest's actual and documented out-of-pocket costs and expenses (including reasonable legal fees and accountants’ fees) incurred solely in connection with the negotiation of this Agreement up to a maximum amount of [*] (the “Expense Payment”). Except as expressly
45
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
set forth herein, each Party shall be responsible for and bear all of its own costs and expenses with regard to the negotiation and consummation of the transactions contemplated by this Agreement. Notwithstanding the foregoing, each Party represents and warrants to the other that the other Party will not be liable for any brokerage commission, finder’s fee, or other like payment in connection with the transactions contemplated hereby because of any action taken by, or agreement or understanding reached by, that Party. If, after the A&R Effective Date, Company requests an amendment of this Agreement in connection with any restructuring, reorganization, or similar transaction to which Company or any Affiliate of Company is a party, [*].
11.5
Relationship of the Parties. Nothing in this Agreement is intended to be construed so as to suggest that either Party (except as expressly set forth herein) is obligated to provide, directly or indirectly, any advice, consultations, or other services to the other Party. Neither Party shall have any responsibility for the hiring, termination, or compensation of the other Party’s employees or for any employee benefits of such employee. No employee or representative of a Party shall have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner whatsoever or to create or impose any contractual or other liability on the other Party without such Party’s approval. For all purposes and notwithstanding any other provision of this Agreement to the contrary, each Party’s legal relationship under this Agreement to the other Party shall be that of independent contractor. This Agreement is not a partnership agreement, and nothing in this Agreement shall be construed to establish a relationship of co-partners or joint venturers between the Parties for any purpose, including any Tax purpose.
11.6
Successors and Assigns. Neither this Agreement nor any rights or obligations hereunder may be assigned in whole or in part by either Party, by operation of law or otherwise, without the prior written consent of the other Party (not to be unreasonably withheld, conditioned or delayed), provided that, notwithstanding the foregoing: (a) subject to the terms of any [*], NovaQuest may, upon delivery of reasonable written notice to Company, (i) assign, sell, or otherwise transfer this Agreement to an Affiliate of NovaQuest, and (ii) assign, sell, pledge, contribute, or otherwise transfer, in whole or in part, its rights to receive any payments under this Agreement, its rights to enforce such payment rights, and its rights to conduct or request audits or receive information and audit findings under ARTICLE Vto any Person that is not a Company Competitor, and such Person may assign, sell, pledge, contribute, or otherwise transfer such rights to another Person that is not a Company Competitor; and (b) Company may assign, sell, pledge, contribute or otherwise transfer its rights or obligations hereunder in accordance with Section 8.2and Section 8.4. This Agreement shall be binding upon, and subject to the terms of this Section 11.6, inure to the benefit of the Parties hereto, their permitted successors, legal representatives and assigns, provided that [*]. Any assignment or attempted assignment not in accordance with this Section 11.6shall be null and void. Company shall maintain at one of its offices a register for the recordation of the names and addresses of the Parties and the commitments of, and principal amounts (and stated interest) under the Agreement owing to, each Party pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive absent manifest error, and the Parties shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Party hereunder for all purposes of this Agreement. The Register shall be available for inspection by the Parties, at any reasonable time
46
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
and from time to time upon reasonable prior notice. The Parties agree that the foregoing is intended to ensure that the Agreement is in “registered form” within the meaning of Treasury Regulation Section 5f.103-1(c) and shall be interpreted consistently therewith. For avoidance of doubt, Company may assign, sell, pledge, contribute or otherwise transfer its rights or obligations under such portions of Astellas Revenue that are not part of the Revenue Interest Payments due and payable to NovaQuest.
11.7
Notices. All notices, consents, waivers, requests, and other communications hereunder shall be in writing and shall be delivered in person, sent by confirmed electronic mail, sent by overnight courier (e.g., Federal Express), confirmed facsimile transmission or posted by registered or certified mail, return receipt requested, with postage prepaid, to following addresses of the Parties:
If to Company:
Kyntra Bio, Inc.
350 Bay Street, Suite 100 #6009
San Francisco, CA 94133
[*]
with a copy (which shall not constitute notice)to:
Goodwin Procter LLP
520 Broadway, Suite 500
Santa Monica, CA 90401
[*]
If to NovaQuest:
NQ Project Phoebus, L.P.
4208 Six Forks Road, Suite 920
Raleigh, NC 27609
[*]
with a copy to:
Wyrick Robbins Yates & Ponton LLP
4101 Lake Boone Trail, Suite 300
Raleigh, North Carolina 27607
[*]
or to such other address or addresses as NovaQuest or Company may from time to time designate by notice as provided herein. Any such notice shall be deemed given: (a) when actually received when so delivered personally or by overnight courier; (b) if mailed, other than during a period of general discontinuance or disruption of postal service due to strike, lockout or otherwise, on the [*] after its postmarked date thereof; or (c) if sent by e-mail with acknowledgement of receipt,
47
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
transmission on the date sent if such day is a Business Day or the next following Business Day if such day is not a Business Day.
11.8
Severability. If any provision hereof should be held invalid, illegal, or unenforceable in any jurisdiction, then the Parties shall negotiate in good faith a valid, legal, and enforceable substitute provision that most nearly reflects the original intent of the Parties. All other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties as nearly as may be possible. Such invalidity, illegality, or unenforceability shall not affect the validity, legality, or enforceability of such provision in any other jurisdiction. Nothing in this Agreement shall be interpreted so as to require a Party to violate any Applicable Law.
11.9
Waiver. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. No waiver by any Party of any term or condition of this Agreement, in any one or more instances, shall be deemed to be, or construed as, a waiver of the same or any other term or condition of this Agreement on any future occasion.
11.10
Entire Agreement. This Agreement, and any [*], including any Exhibits or Schedules to any the foregoing, set forth all of the covenants, promises, agreements, warranties, representations, conditions, and understandings between the Parties relating to the subject matter hereof and thereof and supersedes and terminates all prior agreements and understandings between the Parties. There are no covenants, promises, agreements, warranties, representations, conditions, or understandings, either oral or written, between the Parties relating to the subject matter hereof other than as set forth in this Agreement or [*]. The Parties acknowledge and agree that the Parties’ respective rights and obligations with regard to the subject matter herein are enshrined in this Agreement. Any conflict or inconsistency between the main body of this Agreement, the Exhibits, or Schedules, or any other documents to be delivered pursuant hereto shall be resolved in accordance with the following order of priority: (a) main body of this Agreement; (b) Exhibits and Schedules; and (c) other documents.
11.11
Third-Party Beneficiaries. Except with regard to the NovaQuest Indemnitees under ARTICLE X, all rights, benefits, and remedies under this Agreement are solely intended for the benefit of the Parties (including their permitted successors and assigns), and no Third Party (except the NovaQuest Indemnitees with regard to their rights, benefits, and remedies under ARTICLE X and except for the Parties’ permitted successors and assigns) shall have any rights whatsoever to: (a) enforce any obligation contained in this Agreement; (b) seek a benefit or remedy for any breach of this Agreement; or (c) take any other action relating to this Agreement under any legal theory, including actions in contract, tort (including negligence, gross negligence and strict liability), or as a defense, setoff, or counterclaim to any action or claim brought or made by the Parties (or any of their permitted successors and assigns).
11.12
Interpretation. When a reference is made in this Agreement to Articles, Sections, Schedules, or Exhibits, such reference shall be to an Article, Section, Schedule, or Exhibit to this Agreement unless otherwise indicated. The words “include,” “includes,” and “including” when
48
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
used herein shall be deemed in each case to be followed by the words “without limitation” and shall not be construed to limit any general statement that it follows to the specific or similar items or matters immediately following it. The headings and captions in this Agreement are for convenience and reference purposes only and shall not be considered a part of or affect the construction or interpretation of any provision of this Agreement. Unless specified otherwise, all statements of, or references to, monetary amounts in this Agreement are to Dollars. Each accounting term used herein that is not specifically defined herein shall have the meaning given to it under GAAP or IFRS, as applicable, but only to the extent consistent with its usage and the other definitions in this Agreement. Provisions that require that a Party or the Parties “agree,” “consent,” “approve,” or the like shall require that such agreement, consent, or approval be specific and in writing, whether by written agreement, letter, approved minutes, or otherwise. Words of any gender include the other gender, and words using the singular or plural number also include the plural or singular number, respectively. Neither Party hereto shall be deemed to be the drafter of this Agreement for the purposes of construing this Agreement against one Party or the other. If any notice or other action or omission is required to be taken by a Party under this Agreement on a day that is not a Business Day, then such notice or other action or omission shall be deemed to require to be taken on the next occurring Business Day.
11.13
Amendments. This Agreement may be amended, modified, or supplemented only by a written amendment or agreement signed by an authorized officer of both NovaQuest and Company.
11.14
No Implied Licenses. Each Party acknowledges that the rights granted in this Agreement are limited to the scope expressly granted, and all other rights to each Party’s respective technologies and intellectual property rights are expressly reserved to the Party owning or controlling such technologies and intellectual property rights.
11.15
Time. Time is of the essence with respect to this Agreement and each of its provisions.
11.16
Counterparts. This Agreement may be executed in any number of counterparts with the same effect as if each of the parties hereto had signed the same document. All counterparts shall be construed together and shall constitute one agreement. This Agreement, to the extent signed and delivered by means of a facsimile machine or via e‑mail in .pdf file format, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.
11.17
Electronic Signatures. Any signature (including any electronic symbol or process attached to, or associated with, a contract or other record and adopted by a Person with the intent to sign, authenticate, or accept such contract or record) hereto or to any other certificate, document, or instrument related to this Agreement, and any contract formation or record-keeping through electronic means, shall have the same legal validity and enforceability as a manually executed signature or use of a paper-based recordkeeping system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any similar state law based on the Uniform Electronic Transactions Act, and the Parties hereby waive any objection to the contrary.
49
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
11.18
Further Assurances. Each of the Parties hereto shall execute and deliver such additional documents, certificates, and instruments and shall perform such additional acts as may be reasonably requested and necessary or appropriate to carry out the purposes and intent and all of the provisions of this Agreement and to consummate all of the transactions contemplated by this Agreement.
11.19
Remedies. Neither the failure nor any delay by any Party in exercising any right, power, or privilege under this Agreement will operate as a waiver of such right, power, or privilege, and no single or partial exercise of such right, power, or privilege will preclude any other or further exercise of such right, power, or privilege or the exercise of any other right, power, or privilege. Unless specifically and expressly stated in this Agreement as exclusive, each remedy of the Parties specified in this Agreement is not exclusive, and, subject to the terms of this Agreement, is cumulative. The Parties shall be entitled to pursue any available legal or equitable remedy for breach of this Agreement or any provision hereof.
[Signature page follows]
50
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized representatives as of the A&R Effective Date.
Kyntra Bio, Inc.
By: \s\ [*]
Name: [*]
Title: [*]
[Signature Page to NovaQuest – Kyntra Amended & Restated Revenue Interest Financing Agreement]
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized representatives as of the A&R Effective Date.
NQ Project Phoebus, L.P.
By: NQ POF V GP, Ltd, its general partner
By: \s\ [*]
Name: [*]
Title: [*]
[Signature Page to NovaQuest – Kyntra Amended & Restated Revenue Interest Financing Agreement]
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
Exhibit A
Reserved
[Exhibit A to NovaQuest – Kyntra Amended & Restated Revenue Interest Financing Agreement]
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
Exhibit B
Astellas EMEA Agreement
[Attached]
[Exhibit B to NovaQuest – NovaQuest – Kyntra Amended & Restated Revenue Interest Financing Agreement]
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
Exhibit C
[Reserved]
[Exhibit C to NovaQuest – NovaQuest – Kyntra Amended & Restated Revenue Interest Financing Agreement]
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
Exhibit D
Compound

The chemical compound or bulk active pharmaceutical compound, known as FG-4592, whose specific INN name is roxadustat with CAS number 808118-40-3
[Exhibit D to NovaQuest – NovaQuest – Kyntra Amended & Restated Revenue Interest Financing Agreement]
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
Schedule 7.1(e)
Product Patents
[*].
[Schedule 7.1(e) to NovaQuest – NovaQuest – Kyntra Amended & Restated Revenue Interest Financing Agreement]
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
Schedule 7.1(f)
Litigation
[*].
[Schedule 7.1(f) to NovaQuest – NovaQuest – Kyntra Amended & Restated Revenue Interest Financing Agreement]
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
Schedule 7.1(h)
Material Contracts
[*].
[Schedule 7.1(h) to NovaQuest – NovaQuest – Kyntra Amended & Restated Revenue Interest Financing Agreement]
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.
Schedule 7.1(i)
Certain Regulatory Matters
•
[*]
[Schedule 7.1(i) to NovaQuest – NovaQuest – Kyntra Amended & Restated Revenue Interest Financing Agreement]
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted or excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private and confidential.